Document:

Buy.com Inc. 2005 Equity Incentive Plan

 Exhibit 10.4 
  
 Buy.com Inc. 
 2005 Equity Incentive Plan 
  
 Article 1

  
 General Provisions 
  
 1.1. Purpose of the Plan. This Plan is intended to promote the
interests of the Corporation by providing eligible persons, who are employed by or serving the Corporation or any Parent or Subsidiary, with the opportunity to acquire a proprietary interest, or increase their proprietary interest, in the
Corporation as an incentive for them to continue in such employ or service. 
  
 Capitalized terms shall have the meanings assigned to such terms in the attached Appendix. 
  
 1.2. Structure of the Plan. 
  
 A. The Plan shall be divided into three separate equity incentive programs: 
  
 (i) the Discretionary Option Grant Program under which eligible persons may, at the discretion of the Plan
Administrator, be granted options to purchase shares of Common Stock; 
  
 (ii) the Stock Issuance Program under which eligible persons may, at the discretion of the Plan Administrator, be issued shares of Common Stock (or rights to receive shares of Common Stock, or a cash payment equal to
the Fair Market Value of the shares, at some future date) directly, either through the immediate purchase of such shares or as a bonus for services rendered the Corporation (or any Parent or Subsidiary); and 
  
 (iii) the Stock Appreciation Rights Program under which
eligible persons may, at the discretion of the Plan Administrator, receive an amount equal to the appreciation in a certain number of shares of Common Stock in the form of either cash or shares. 
  
 B. The Plan Administrator is also authorized to grant performance awards to
eligible persons subject to the terms of the Plan and any applicable award agreement. A performance award granted under the Plan (i) may be denominated or payable in cash, shares of Common Stock, other securities, other awards or other property
and (ii) shall confer on the holder thereof the right to receive payments, in whole or in part, upon the achievement of such performance goals during such performance periods as the Plan Administrator shall establish. Subject to the terms of
the Plan and any applicable award agreement, the performance goals to be achieved during any performance period, the length of any performance period, the amount of any performance award granted, the amount of any payment or transfer to be made
pursuant to any performance award and any other terms and conditions of any performance award shall be determined by the Plan Administrator. 

 The Plan Administrator is authorized to grant to eligible persons such other awards that are denominated
or payable in, valued in whole or in part by reference to, or otherwise based on or related to, shares of Common Stock, as are deemed by the Plan Administrator to be consistent with the purpose of the Plan; provided, however, that such grants must
comply with applicable law. Subject to the terms of the Plan and any applicable award agreement, the Plan Administrator shall determine the terms and conditions of such awards. Shares or other securities delivered pursuant to a purchase right
granted hereunder shall be purchased for such consideration, which may be paid by such method or methods and in such form or forms (including, without limitation, cash, shares of Common Stock, other securities, other awards or other property or any
combination thereof), as the Plan Administrator shall determine. 
  
 C. The provisions of Articles 1 and 5 shall apply to all equity programs under the Plan and shall govern the interests of all persons under the Plan. 
  

1.3. Administration of the Plan. 
  
 A. The Primary Committee and the Board shall have concurrent authority to administer all programs and awards under the Plan with respect to
Section 16 Insiders. (Options and stock appreciation rights that are granted to Section 16 Insiders by the Board will not be exempt from the million dollar compensation deduction limitation of Code Section 162(m).) Administration of
the Discretionary Option Grant, and Stock Appreciation Rights and Stock Issuance Programs with respect to all other persons eligible to participate in those programs may, at the Board’s discretion, be vested in the Primary Committee or a
Secondary Committee, or the Board may retain the power to administer those programs with respect to all such persons. However, any discretionary option grants or stock issuances or stock appreciation rights for members of the Primary Committee must
be authorized by a disinterested majority of the Board. 
  
 B. The
Plan Administrator shall have the absolute discretion to grant options in accordance with the Discretionary Option Grant Program, to grant stock appreciation rights in accordance with the Stock Appreciation Rights Program, or to effect stock
issuances in accordance with the Stock Issuance Program. 
  
 C.
The Plan Administrator shall have the authority (subject to the provisions of the Plan) to determine, (i) with respect to the option grants made pursuant to the Discretionary Option Grant Program, which eligible persons are to receive such
grants, the time or times when those grants are to be made, the number of shares to be covered by each such grant, the status of the granted option as either an Incentive Option or a Non-Statutory Option, the time or times when each option is to
become exercisable, the exercise price, the vesting schedule (if any) applicable to the shares subject to the option and the maximum term for which the option is to remain outstanding, (ii) with respect to the stock appreciation right grants
made pursuant to the Stock Appreciation Rights Program, which eligible persons are to receive such grants, the time or times when those grants are to be made, the number of shares to be covered by each such grant, the vesting schedule (if any)
applicable to the shares subject to the grant and the maximum term for which the grant is to remain outstanding, and (iii) with respect to stock issuances pursuant to the Stock Issuance Program, which eligible persons are to receive such
issuances, the time or times when the issuances are to be made, the number of shares to be issued to each 

  

 2 

 
Participant, the vesting schedule (if any) applicable to the issued shares and the consideration for such shares. 
  
 D. The Plan Administrator shall have the authority (subject to the provisions
of the Plan) to establish such rules and procedures as it may deem appropriate for proper administration of the Discretionary Option Grant, the Stock Appreciation Rights Grant and Stock Issuance Programs and to make such determinations under, and
issue such interpretations of, the provisions of those programs and any outstanding options or stock issued under the Plan as it may deem necessary or advisable. Decisions of the Plan Administrator under the Plan shall be final and binding on all
parties who have an interest in the Discretionary Option Grant, the Stock Appreciation Rights Grant and Stock Issuance Programs under its jurisdiction or any option granted or stock issued under the Plan. 
  
 E. Members of the Primary Committee or any Secondary Committee shall serve
for such period of time as the Board may determine and may be removed by the Board at any time. The Board may also at any time terminate the functions of the Primary Committee or any Secondary Committee and reassume all powers and authority
previously delegated to such committee. 
  
 F. To the maximum
extent permitted by law, the Corporation shall indemnify each member of the Board who acts as the Plan Administrator, as well as any other Employee of the Corporation with duties under the Plan, against expenses and liabilities (including any amount
paid in settlement) reasonably incurred by the individual in connection with any claims against the individual by reason of the performance of the individual’s duties under the Plan, unless the losses are due to the individual’s gross
negligence or lack of good faith. The Corporation will have the right to select counsel and to control the prosecution or defense of the suit. In the event that more than one person who is entitled to indemnification is subject to the same claim,
all such persons shall be represented by a single counsel, unless such counsel advises the Corporation in writing that he or she cannot represent all such persons under applicable rules of professional responsibility. The Corporation will not be
required to indemnify any person for any amount incurred through any settlement unless the Corporation consents in writing to the settlement. 
  
 1.4. Eligibility. 
  
 The persons eligible to participate in the Discretionary Option Grant, the Stock Appreciation Rights and Stock Issuance Programs are as follows:

  
 (i) Employees, 
  
 (ii) members of the Board and the members of the board of
directors of any Parent or Subsidiary, and 
  
 (iii) independent contractors who provide services to the Corporation (or any Parent or Subsidiary). 
  

 3 

 1.5. Stock Subject to the Plan. 
  
 A. The shares of Common Stock issuable under the Plan shall be shares of
authorized but unissued or reacquired shares of Common Stock, including shares repurchased by the Corporation on the open market. The maximum number of shares of Common Stock that may be issued and outstanding or subject to options outstanding under
the Plan shall not exceed 1,100,000 shares. 
  
 B. No one person
participating in the Plan may receive options, stock appreciation rights and direct stock issuances pursuant to the Plan for more than 500,000 shares of Common Stock in the aggregate per calendar year. 
  
 C. Shares of Common Stock subject to outstanding options shall be available
for subsequent issuance under the Plan to the extent (i) the options expire or terminate for any reason prior to their being exercised in full or (ii) the options are cancelled in accordance with the cancellation-regrant provisions of the
Discretionary Option Grant Program. Unvested shares issued under the Plan and subsequently cancelled or repurchased by the Corporation at a price per share not greater than the option exercise or direct issue price paid per share pursuant to the
Corporation’s repurchase rights under the Plan shall be added back to the number of shares of Common Stock reserved for issuance under the Plan and shall accordingly be available for reissuance through one or more subsequent option grants or
direct stock issuances under the Plan. However, should the exercise price of an option granted pursuant to the Plan be paid with shares of Common Stock or should shares of Common Stock otherwise issuable pursuant to the Plan be withheld by the
Corporation in satisfaction of the withholding taxes incurred in connection with the exercise of an option or the vesting of a stock issuance made pursuant to the Plan, then the number of shares of Common Stock available for issuance pursuant to the
Plan shall be reduced by the gross number of shares for which the option is exercised or which vest under the stock issuance, and not by the net number of shares of Common Stock issued to the holder of such option or stock issuance. 
  
 D. Should any change be made to the Common Stock by reason of any stock
split, stock dividend, reverse stock split, recapitalization, combination of shares, exchange of shares or other change affecting the outstanding Common Stock as a class without the Corporation’s receipt of consideration, appropriate
adjustments shall be made to (i) the maximum number and/or class of securities issuable pursuant to the Plan, (ii) the maximum number and/or class of securities for which any one person may be granted options and direct stock issuances
pursuant to the Plan per calendar year, (iii) the number and/or class of securities and the exercise price per share in effect under each outstanding option granted pursuant to the Plan, and (iv) the maximum number and/or class of
securities by which the share reserve is to increase automatically each calendar year pursuant to the provisions of Section 1.5(B). Such adjustments to the outstanding options are to be effected in a manner that shall preclude the enlargement
or dilution of rights and benefits under such options. The adjustments determined by the Plan Administrator shall be final. In no event shall any such adjustments be made in connection with the conversion of one or more outstanding shares of the
Corporation’s preferred stock or warrants into shares of Common Stock. 
  

 4 

 Article 2 
  

Discretionary Option Grant Program 
  
 2.1. Exercise Price. 
  
 A. The exercise price per share shall be fixed by the Plan Administrator but shall not be less than 100% of the Fair Market Value per share of Common
Stock on the date of grant. 
  
 B. The exercise price shall become
immediately due upon exercise of the option and shall, subject to the provisions of Section 6.1 and the documents evidencing the option, be payable in one or more of the forms specified below: 
  
 (i) cash or check made payable to the Corporation,

  
 (ii) with shares of Common Stock held for the
requisite period, if any, necessary to avoid a charge to the Corporation’s earnings for financial reporting purposes and valued at Fair Market Value on the Exercise Date, or 
  
 (iii) to the extent the option is exercised for vested shares, through a special sale and remittance
procedure pursuant to which Optionee shall concurrently provide irrevocable instructions to (1) a Corporation-designated brokerage firm to effect the immediate sale of the purchased shares and remit to the Corporation, out of the sale proceeds
available on the settlement date, sufficient funds to cover the aggregate exercise price payable for the purchased shares plus all applicable income and employment taxes required to be withheld by the Corporation by reason of such exercise and
(2) the Corporation to deliver the certificates for the purchased shares directly to such brokerage firm in order to complete the sale. 
  
 Except to the extent such sale and remittance procedure is utilized, payment of the exercise price for the purchased shares must be made on the Exercise
Date. 
  
 2.2. Exercise and Term of Options. Each
option shall be exercisable at such time or times, during such period and for such number of shares as shall be determined by the Plan Administrator and set forth in the documents evidencing the option. However, no option shall have a term in excess
of ten years measured from the date that the option is granted. 
  
 2.3. Effect of Termination of Service. 
  
 A. The following provisions shall govern the exercise of any options granted to an Optionee other than a member of the Board pursuant to the Discretionary Option Grant Program that are outstanding at the time Optionee’s Service ceases:

  
 (i) Immediately upon Optionee’s
cessation of Service, each option shall terminate with respect to the unvested shares subject to such option. 
  

 5 

 (ii) Should Optionee’s Service be terminated for Misconduct or should Optionee
otherwise engage in Misconduct, then each option shall terminate immediately with respect to all shares subject to such option. 
  
 (iii) Should Optionee’s Service terminate for reasons other than Misconduct, then each option with respect to vested shares shall
remain exercisable during such period of time after Optionee’s Service ceases as shall be determined by the Plan Administrator and set forth in the documents evidencing the option, but no option shall be exercisable after it terminates. During
the applicable post-Service exercise period, the option may not be exercised in the aggregate for more than the number of vested shares for which the option is exercisable on the date Optionee’s Service ceases. Upon the expiration of the
applicable exercise period or (if earlier) upon the termination of the option, each option shall terminate with respect to any vested shares subject to the options. 
  
         B. The following provisions shall govern the exercise of any options granted
to an Optionee acting as a member of the Board pursuant to the Discretionary Option Grant Program that are outstanding at the time the director’s service ceases: 
  
 (i) Should Optionee’s service as a Board member cease for any reason other than death or Permanent
Disability while one or more options granted pursuant to this Discretionary Option Grant Program are outstanding and exercisable, then each such option shall remain exercisable until the earlier of (i) the Expiration Date or (ii) the
expiration of the three-year period measured from the date Optionee’s Board service ceases. 
  
 (ii) Should Optionee’s service as a Board member cease by reason of death or Permanent Disability, then each outstanding option
granted pursuant to this Discretionary Option Grant Program shall immediately become exercisable for all the shares of Common Stock at the time subject to that option, and the option may be exercised for any or all of those shares as fully vested
shares until the earlier of (i) the Expiration Date or (ii) the expiration of the three-year period measured from the date Optionee’s Board service ceases. 
  
 (iii) Each option granted pursuant to this Discretionary Option Grant Program that is outstanding but not
exercisable at the time of Optionee’s cessation of Board service shall immediately terminate with respect to all shares of Common Stock for which the option is not otherwise at that time exercisable. Upon the expiration of the post-termination
exercise period or (if earlier) upon the Expiration Date, the option shall terminate and cease to be outstanding for any shares for which the option has not been exercised. 
  
         C. Notwithstanding that there may be adverse tax and accounting consequences
to doing so, the Plan Administrator shall have complete discretion, exercisable either at the time an option is granted or at any time while Optionee remains in Service, to: 
  
 (i) extend the period of time for which the option is to remain exercisable following Optionee’s
cessation of Service, but in no event beyond the Expiration Date, and/or 
  
 (ii) permit the option to be exercised, during the applicable post-Service exercise period, not only with respect to the number of vested shares of Common Stock 

  

 6 

 
for which such option is exercisable at the time of Optionee’s cessation of Service but also with respect to one or more additional installments in
which Optionee would have vested had Optionee continued in Service. 
  
 2.4. Stockholder Rights. The holder of an option shall have no stockholder rights with respect to the shares subject to the option until such person shall have exercised the option, paid the exercise price and become the
holder of record of the purchased shares. 
  
 2.5. Unvested
Shares. The Plan Administrator shall have the discretion to grant options that are exercisable for unvested shares of Common Stock. Should Optionee’s Service cease while the shares issued upon the exercise of Optionee’s option are
still unvested, the Corporation shall have the right to repurchase any or all of those unvested shares at a price per share equal to the lower of (i) the exercise price paid per share or (ii) the Fair Market Value per share at the
time Optionee’s Service ceases. Once the Corporation exercises its repurchase right, Optionee shall have no further stockholder rights with respect to those shares. The terms upon which such repurchase right shall be exercisable (including the
period and procedure for exercise and the appropriate vesting schedule for the purchased shares) shall be established by the Plan Administrator and set forth in the document evidencing such repurchase right. Any repurchases must be made in
compliance with the relevant provisions of Delaware law. 
  
 2.6. Limited Transferability of Options. An Incentive Option shall be exercisable only by Optionee during his or her lifetime and shall not be assignable or transferable other than by will or by the laws of inheritance
following Optionee’s death. A Non-Statutory Option may be assigned in whole or in part during Optionee’s lifetime to one or more of Optionee’s family members (as such term is defined in the instructions to Form S-8), or to
Optionee’s former spouse through a gift or domestic relations order. The terms applicable to the assigned portion shall be the same as those in effect for the option immediately prior to such assignment and shall be set forth in such documents
issued to the assignee as the Plan Administrator may deem appropriate. 
  
 2.7. Incentive Options. The terms specified below shall be applicable to all Incentive Options. Except as modified by the provisions of this Section 2.7, all the provisions of Articles 1, 2 and 5 shall be applicable to
Incentive Options. Options that are specifically designated as Non-Statutory Options are not subject to the terms of this Section 2.7. 
  
 A. Eligibility. Incentive Options may be granted only to Employees. 
  
 B. Dollar Limitation. The aggregate Fair Market Value of the shares of Common Stock (determined as of the date or
dates of grant) for which one or more options granted to any Employee pursuant to the Plan (or any other option plan of the Corporation or any Parent or Subsidiary) may for the first time become exercisable as Incentive Options during any one
calendar year shall not exceed $100,000. To the extent that an Optionee’s options exceed that limit, they will be treated as Non-Statutory Options (but all of the other provisions of the option shall remain applicable), with the first options
that were awarded to Optionee to be treated as Incentive Options. 
  

 7 

 C. 10% Stockholder. If any Employee to whom an Incentive Option is granted is a 10% Stockholder,
then the Expiration Date shall be not more than five years from the date the option is granted. 
  
 2.8. Change in Control/Proxy Contest. 
  
 A. In the event a Change in Control occurs, the shares of Common Stock at the time subject to each outstanding option granted pursuant to this
Discretionary Option Grant Program shall automatically vest in full so that each such option shall, immediately prior to the effective date of the Change in Control, become exercisable for all of the shares of Common Stock at the time subject to
such option. However, the shares subject to an outstanding option shall not become vested pursuant to the preceding sentence if (i) the option is to be assumed by the successor corporation (or parent thereof) or otherwise is to be continued in
full force and effect pursuant to the terms of the Change in Control transaction, or (ii) the option is to be replaced with a cash incentive program of any successor corporation (or parent thereof) which preserves the spread existing at the
time of the Change in Control on any unvested shares and provides for subsequent payout of that spread no later than the time Optionee would vest in those shares subject to the option, or (iii) the acceleration of the vesting of such option is
subject to other limitations imposed by the Plan Administrator. 
  
 B. All outstanding repurchase rights under the Discretionary Option Grant Program shall terminate automatically, and the shares of Common Stock subject to those terminated rights shall immediately vest in full, immediately prior to the
consummation of a Change in Control, except to the extent: (i) those repurchase rights are to be assigned to the successor corporation (or parent thereof) or are otherwise to continue in full force and effect pursuant to the terms of the Change
in Control transaction, (ii) any property (including cash payments) issued with respect to any unvested shares of Common Stock is to be held in escrow and released no later than as provided by the vesting schedule in effect for the unvested
shares or (iii) such accelerated vesting is precluded by other limitations imposed by the Plan Administrator. 
  
 C. Immediately following the consummation of the Change in Control, all outstanding options granted pursuant to the Discretionary Option Grant Program
shall terminate, except to the extent assumed by the successor corporation (or parent thereof) or otherwise continued in full force and effect pursuant to the terms of the Change in Control transaction. 
  
 D. Each option granted pursuant to the Discretionary Option Grant Program
that is assumed or otherwise continued in effect in connection with a Change in Control shall be appropriately adjusted, immediately after such Change in Control, to apply to the number and class of securities which would have been issuable to
Optionee in consummation of such Change in Control had the option been exercised immediately prior to such Change in Control. Appropriate adjustments to reflect such Change in Control shall also be made to (i) the exercise price payable per
share under each outstanding option, provided the aggregate exercise price payable for such securities shall remain the same, (ii) the maximum number and/or class of securities available for issuance over the remaining term of the Plan,
(iii) the maximum number and/or class of securities for which any one person may be granted options and direct stock issuances pursuant to the Plan per calendar year and (iv) the maximum number and/or class of 
  

 8 

 securities by which the share reserve is to increase automatically each calendar year. To the extent the holders of
Common Stock receive cash consideration in whole or part for their Common Stock in consummation of the Change in Control, the successor corporation may, in connection with the assumption of the outstanding options granted pursuant to the
Discretionary Option Grant Program, substitute one or more shares of its own common stock with a fair market value equivalent to the cash consideration paid per share of Common Stock in such Change in Control transaction. 
  
 E. Among its discretionary powers, the Plan Administrator shall have the
ability to structure an option (either at the time the option is granted or at any time while the option remains outstanding) so that some or all of the shares subject to that option shall automatically become vested (and the option shall become
exercisable for such shares) upon (i) the occurrence of a Change in Control, (ii) the consummation of a Proxy Contest, (iii) the occurrence of any other specified event and/or (iv) the Involuntary Termination of Optionee’s
Service within a designated period of time following a specified event. In addition, the Plan Administrator may provide that one or more of the Corporation’s repurchase rights with respect to some or all of the shares held by Optionee upon
(a) the occurrence of a Change in Control, (b) the consummation of a Proxy Contest, (c) upon the occurrence of any other specified event and/or (d) the Involuntary Termination of Optionee’s Service within a designated period
of time following a specified event shall immediately terminate and all of the shares shall become vested. 
  
 F. The portion of any Incentive Option accelerated in connection with a Change in Control or Proxy Contest shall remain exercisable as an Incentive Option
only to the extent the $100,000 limitation set forth in Section 2.7(B) is not exceeded. To the extent such dollar limitation is exceeded, the accelerated portion of such option shall be exercisable as a Non-Statutory Option under the federal
tax laws. 
  
 Article 3 
  
 Stock Issuance Program 
  
 3.1. Purchase Price. 
  
 A. The purchase price per share shall be fixed by the Plan Administrator.

  
 B. Shares of Common Stock (or rights to receive shares of
Common Stock) may be issued pursuant to the Stock Issuance Program for any consideration which the Plan Administrator may deem appropriate, including for past services rendered to the Corporation (or any Parent or Subsidiary). 
  
 3.2. Vesting Provisions. 
  
 A. Shares of Common Stock (or rights to receive shares of Common Stock)
issued pursuant to the Stock Issuance Program may, in the discretion of the Plan Administrator, be fully and immediately vested upon issuance or may vest in one or more installments over Participant’s period of Service or upon attainment of
specified performance objectives. Shares of Common Stock may also be issued pursuant to the Stock Issuance Program pursuant to 
  

 9 

 awards that entitle the recipients to receive those shares upon the attainment of designated performance goals or the
satisfaction of specified Service requirements. Shares of Common Stock (or rights to receive shares of Common Stock) shall be subject to such restrictions as the Plan Administrator may impose, which restrictions may lapse separately or in
combination at such time or times, in such installments or otherwise as the Plan Administrator may deem appropriate. 
  
 B. Any new, substituted or additional securities or other property (including money paid other than as a regular cash dividend) which Participant may have
the right to receive with respect to Participant’s unvested shares of Common Stock by reason of any stock dividend, stock split, reverse stock split, recapitalization, combination of shares, exchange of shares or other change affecting the
outstanding Common Stock as a class without the Corporation’s receipt of consideration shall be issued subject to (i) the same vesting requirements applicable to Participant’s unvested shares of Common Stock and shall be treated as if
they had been acquired on the same date as such shares and (ii) such escrow arrangements as the Plan Administrator shall deem appropriate. 
  
 C. Should Participant cease to remain in Service while one or more shares of Common Stock issued pursuant to the Stock Issuance Program are unvested or
should the performance objectives not be attained with respect to one or more such unvested shares of Common Stock, then the Corporation shall have the right to repurchase those shares at a price per share equal to the lower of (i) the
purchase price paid per share or (ii) the Fair Market Value per share on the date Participant’s Service ceases. The terms upon which such repurchase right shall be exercisable shall be established by the Plan Administrator and set forth in
the document evidencing such repurchase right. Any repurchases must be done in compliance with applicable state corporate law. 
  
 D. The Plan Administrator may in its discretion waive the surrender and cancellation of one or more unvested shares of Common Stock (or other assets
attributable thereto) that would otherwise occur upon the cessation of Participant’s Service or the non-attainment of the performance objectives applicable to those shares. Such waiver may be effected at any time and shall result in the
immediate vesting of Participant’s interest in the shares of Common Stock as to which the waiver applies. 
  
 E. Outstanding share right awards granted pursuant to the Stock Issuance Program shall automatically terminate, and no shares of Common Stock shall
actually be issued in satisfaction of those awards, if the performance goals or Service requirements established for such awards are not attained or satisfied. The Plan Administrator, however, shall have the discretionary authority to issue shares
of Common Stock under one or more outstanding share right awards as to which the designated performance goals or Service requirements have not been attained or satisfied. 
  

 10 

 3.3. Stockholder Rights. Subject to the terms of the Stock Issuance Agreement,
Participant shall have full stockholder rights with respect to any shares of Common Stock issued to Participant pursuant to the Stock Issuance Program, whether or not Participant’s interest in those shares is vested. Accordingly, Participant
shall have the right to vote such shares and to receive any regular cash dividends paid on such shares. Cash dividends constitute taxable compensation to Participant and are deductible by the Corporation (unless Participant has made an election
under Section 83(b) of the Code). 
  
 3.4. Change in
Control/Proxy Contest. 
  
 A. Upon the occurrence of a
Change in Control, all outstanding repurchase rights under the Stock Issuance Program shall terminate automatically, and the shares of Common Stock subject to those terminated rights shall immediately vest in full except to the extent:
(i) those repurchase rights are assigned to the successor corporation (or parent thereof) or are otherwise continue in full force and effect pursuant to the terms of the transaction, (ii) the property (including cash payments) issued with
respect to the unvested shares is held in escrow and released no later than as provided by the vesting schedule in effect for the unvested shares of Common Stock issued to Optionee pursuant to the terms of the Change in Control transaction, or
(iii) such accelerated vesting is precluded by limitations imposed by the Plan Administrator. 
  
 B. The Plan Administrator shall have the discretionary authority, exercisable either at the time the unvested shares are issued or at any time while the
Corporation’s repurchase rights are outstanding, to provide that those rights shall automatically terminate in whole or in part on an accelerated basis, and some or all of the shares of Common Stock subject to those terminated rights shall
immediately vest, upon the occurrence of a Change in Control, a Proxy Contest or another event, or in the event Participant’s Service is Involuntary Terminated within a designated period of time following a specified event. 
  

 11 

 Article 4 
  

Stock Appreciation Rights Program 
  
 4.1. Grant Price. The Plan Administrator is hereby authorized to grant Stock Appreciation Rights (“SARs”) to eligible
persons subject to the terms of the Plan. Each SAR granted under the Plan shall confer on the holder upon exercise the right to receive, as determined by the Plan Administrator, cash or a number of shares of Common Stock equal to the excess of
(a) the Fair Market Value of one share on the date of exercise (or, if the Plan Administrator shall so determine, at any time during a specific period before or after the date of exercise) or (b) the grant price of the SAR as determined by
the Plan Administrator, which grant price shall be not less than 100% of the Fair Market Value of one share on the date of grant of the SAR. Subject to the terms of the Plan, the grant price, term, methods of exercise, dates of exercise, methods of
settlement and any other terms and conditions (including conditions or restrictions on the exercise thereof) of any SAR shall be as determined by the Plan Administrator. 
  
 4.2. Effect of Termination of Service. 
  
 A. The following provisions shall govern the exercise of any SARs granted to an eligible employee other than a member of the
Board pursuant to the Stock Appreciation Rights Program that are outstanding at the time the employee’s Service ceases: 
  
 (i) Immediately upon the employee’s cessation of Service, each SAR that is outstanding but unexercised shall terminate. 

 
 (ii) In the sole discretion of the Plan Administrator,
notwithstanding clause (i) above, should the employee’s Service terminate for reasons other than Misconduct, then each SAR shall remain exercisable during such period of time after the employee’s Service ceases as shall be determined
by the Plan Administrator and set forth in the documents evidencing the SAR, but no SAR shall be exercisable after it terminates. During the applicable post-Service exercise period, the SAR may not be exercised in the aggregate for more than the
number of shares for which the SAR is exercisable on the date the employee’s Service ceases. Upon the expiration of the applicable exercise period or (if earlier) upon the termination of the SAR, each SAR shall terminate with respect to any
shares subject to the SAR. 
  
 B. The following provisions shall
govern the exercise of any SARs granted to a director acting as a member of the Board pursuant to the Stock Appreciation Rights Program that are outstanding at the time the director’s service ceases: 
  
 (i) Should the director’s Service as a Board member
cease for any reason other than death or Permanent Disability while one or more SARs granted pursuant to this Stock Appreciation Rights Program are outstanding and exercisable, then each such SAR shall remain exercisable until the earlier of
(i) the Expiration Date or (ii) the expiration of the three-year period measured from the date the director’s Board Service ceases. 
  
 (ii) Should the director’s Service as a Board member cease by reason of death or Permanent Disability, then each outstanding SAR
granted pursuant to this Stock 
  

 12 

 Appreciation Rights Program shall immediately become exercisable for all of the shares of Common Stock at
the time subject to that SAR, and the SAR may be exercised for any or all of those shares until the earlier of (i) the Expiration Date or (ii) the expiration of the three-year period measured from the date the director’s Board service
ceases. 
  
 (iii) Each SAR granted pursuant to
this Stock Appreciation Rights Program that is outstanding but not exercisable at the time of the director’s cessation of Board service shall immediately terminate with respect to all shares of Common Stock for which the SAR is not otherwise at
that time exercisable. Upon the expiration of the post-termination exercise period or (if earlier) upon the Expiration Date, the SAR shall terminate and cease to be outstanding for any shares for which the SAR has not been exercised. 
  
 C. Notwithstanding that there may be adverse tax and accounting consequences
to doing so, the Plan Administrator shall have complete discretion, exercisable either at the time an SAR is granted or at any time while a holder of an SAR remains in Service, to: 
  
 (i) extend the period of time for which the SAR is to remain exercisable following the holder’s
cessation of Service, but in no event beyond the Expiration Date, and/or 
  
 (ii) permit the SAR to be exercised, during the applicable post-Service exercise period, not only with respect to the number of shares of Common Stock for which such SAR is exercisable at the time of the holder’s
cessation of Service but also with respect to one or more additional installments in which the holder would have vested had the holder continued in Service. 
  
 4.3. Stockholder Rights. The holder of an SAR shall have no stockholder rights with respect to the shares subject to the SAR until
such person shall have exercised the SAR, paid the exercise price and (if the holder elects to receive shares rather than cash) become the holder of record of the purchased shares. 
  
 4.4. Change in Control/Proxy Contest. 
  
 A. In the event a Change in Control occurs, the shares of Common Stock at the time subject to each outstanding SAR granted
pursuant to this Stock Appreciation Rights Program shall automatically vest in full so that each such SAR shall, immediately prior to the effective date of the Change in Control, become exercisable for all of the shares of Common Stock at the time
subject to such SAR. However, the shares subject to an outstanding SAR shall not become vested pursuant to the preceding sentence if (i) the SAR is to be assumed by the successor corporation (or parent thereof) or otherwise is to be continued
in full force and effect pursuant to the terms of the Change in Control transaction, or (ii) the SAR is to be replaced with a cash incentive program of any successor corporation (or parent thereof) which preserves the spread existing at the
time of the Change in Control on any unvested shares and provides for subsequent payout of that spread no later than the time the holder would vest in those shares subject to the option, or (iii) the acceleration of the vesting of such SAR is
subject to other limitations imposed by the Plan Administrator. 
  

 13 

 B. Among its discretionary powers, the Plan Administrator shall have the ability to structure an SAR
(either at the time the SAR is granted or at any time while the SAR remains outstanding) so that some or all of the shares subject to that SAR shall automatically become vested (and the SAR shall become exercisable for such shares) upon (i) the
occurrence of a Change in Control, (ii) the consummation of a Proxy Contest, (iii) the occurrence of any other specified event and/or (iv) the Involuntary Termination of the holder’s Service within a designated period of time
following a specified event. 
  
 Article 5 
  
 Miscellaneous Matters 
  
 5.1. Financing. The Plan Administrator may permit any Optionee
or holder of an SAR to pay the exercise price for shares subject to an option granted under the Discretionary Option Grant Program or shares subject to an SAR under the Stock Appreciation Rights Program by delivering a full-recourse promissory note
bearing a market rate of interest secured by the purchased shares and payable in one or more installments. The Plan Administrator, after considering the potential adverse tax and accounting consequences, shall set the remaining terms of the note. In
no event may the maximum credit available to an Optionee or holder of an SAR exceed the sum of (A) the aggregate option exercise price or purchase price payable for the purchased shares (less the par value of those shares) plus (B) any
applicable income and employment tax liability incurred by Optionee or holder of an SAR in connection with the option exercise or share purchase. Prior to permitting the use of promissory notes as payment under the Plan, the Plan Administrator
should consider the restrictions on doing so imposed by Regulation U. 
  
 5.2. Tax Withholding. 
  
 A. The
Corporation’s obligation to deliver shares of Common Stock upon the exercise of options or the issuance or vesting of such shares granted pursuant to the Plan or its obligations to deliver either cash or shares upon the exercise of SARs shall
be subject to the satisfaction of all applicable income and employment tax withholding requirements. 
  
 B. The Plan Administrator may, in its discretion, provide to any or all holders of Non-Statutory Options or holders of SARs who receive shares of Common
Stock or holders of unvested shares of Common Stock issued pursuant to the Plan (other than non-Employee Board member or independent contractors) the right to use shares of Common Stock in satisfaction of all or part of the withholding taxes to
which such holders may become subject in connection with the exercise of their options or SARs or the vesting of their shares. Such right may be provided to any such holder in either or both of the following formats: 
  
 (i) Stock Withholding: The election to have the
Corporation withhold, from the shares of Common Stock otherwise issuable upon the exercise of such Non-Statutory Option or SAR or the vesting of such shares, a portion of those shares. 
  
 (ii) Stock Delivery: The election to deliver to the Corporation, at the time the Non-Statutory Option
or SAR is exercised or the shares vest, one or more shares of 
  

 14 

 Common Stock previously acquired by such holder (other than in connection with the option or SAR exercise or share
vesting triggering the withholding taxes). 
  
 So as to avoid
adverse accounting treatment, the number of shares that may be withheld for this purpose shall not exceed the minimum number needed to satisfy the applicable income and employment tax withholding rules. 
  
 5.3. Share Escrow/Legends. Unvested shares of Common Stock may,
in the Plan Administrator’s discretion, be held in escrow by the Corporation until Participant’s or Optionee’s interest in such shares vest or may be issued directly to Participant or Optionee with restrictive legends on the
certificates evidencing the fact that Participant or Optionee does not have a vested right to them. 
  
 5.4. Cancellation and Regrant of Options. The Plan Administrator shall have the authority to effect, at any time and from time to time, with
the consent of the affected option holders, the cancellation of any or all outstanding options granted pursuant to the Plan and to grant in substitution new options covering the same or a different number of shares of Common Stock. 
  
 5.5. Effective Date and Term of the Plan. 
  
 A. The Plan shall become effective immediately on the Plan Effective Date.
Options may be granted pursuant to the Discretionary Option Grant at any time on or after the Plan Effective Date. However, no options granted under the Plan may be exercised, and no shares shall be issued under the Plan, until the
Corporation’s stockholders approve the Plan. If such stockholder approval is not obtained within twelve months after the Plan Effective Date, then all options previously granted under this Plan shall terminate and cease to be outstanding, and
no further options shall be granted and no shares shall be issued under the Plan. 
  
 B. The Plan shall serve as the successor to the Predecessor Plan, and no further option grants or direct stock issuances shall be made pursuant to the Predecessor Plan after the Plan Effective Date. 
  
 C. Each outstanding option under the Predecessor Plan shall continue to be
governed solely by the terms of the documents evidencing such option, and no provision of the Plan shall be deemed to affect or otherwise modify the rights or obligations of the holders of such options with respect to their acquisition of shares of
Common Stock. 
  
 D. The Plan shall terminate upon the
earlier of (i) the expiration of the ten year period measured from the date the Plan is adopted by the Board or (ii) termination by the Board. All options and unvested stock issuances outstanding at the time of the
termination of the Plan shall continue in effect in accordance with the provisions of the documents evidencing those options or issuances. 
  

 15 

 5.6. Amendment or Termination. The Board shall have complete and exclusive power and
authority to amend or terminate the Plan or any awards made hereunder. However, no such amendment or termination of the Plan shall adversely affect the rights and obligations with respect to options or unvested stock issuances at the time
outstanding under the Plan unless Optionee or Participant consents to such amendment or termination. In addition, certain amendments may require approval of the Corporation’s stockholders. 
  
 5.7. Regulatory Approvals. 
  
 A. The implementation of the Plan, the granting of any options pursuant to
the Plan and the issuance of any shares of Common Stock (i) upon the exercise of any option or (ii) pursuant to the Stock Issuance Program shall be subject to the Corporation’s procurement of all approvals and permits required by
regulatory authorities having jurisdiction over the Plan, the options granted, and the shares of Common Stock issued, pursuant to it. 
  
 B. No shares of Common Stock or other assets shall be issued or delivered pursuant to the Plan unless and until there shall have been compliance with all
applicable requirements of applicable securities laws, including the filing and effectiveness of the Form S-8 registration statement for the shares of Common Stock issuable pursuant to the Plan, and all applicable listing requirements of any stock
exchange or trading system, including the Nasdaq Stock Market, on which Common Stock is then traded. No shares of Common Stock shall be issued or delivered pursuant to the Plan if doing so would violate any internal policies of the Corporation.

  
 5.8. No Employment or Service Rights. Nothing in
the Plan shall confer upon Optionee or Participant any right to continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Corporation (or any Parent or Subsidiary employing or
retaining such person) or of Optionee or Participant, which rights are hereby expressly reserved by each, to terminate such person’s Service at any time for any reason, with or without cause. 
  
 5.9. No Restraint. Neither the grant of options nor the
issuance of Common Stock under the Plan shall affect the right of the Corporation to undertake any corporate action. 
  
 5.10. Use of Proceeds. Any cash proceeds received by the Corporation from the sale of shares of Common Stock pursuant to the Plan shall be
used for any corporate purpose. 
  

 16 

 Appendix 
  
 The following definitions shall be in effect under the Plan: 
  
 A. Board shall mean the Corporation’s Board of Directors. 
  
 B. Change in Control shall mean a change in ownership or
control of the Corporation effected through any of the following transactions: 
  
 (i) a merger, consolidation or other reorganization unless securities representing more than 50% of the total combined voting power
of the voting securities of the successor corporation are immediately thereafter beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Corporation’s outstanding voting
securities immediately prior to such transaction; 
  
 (ii) a sale, transfer or other disposition of all or substantially all of the Corporation’s assets; or 
  
 (iii) the acquisition, directly or indirectly, by any person or related group of persons (other than the Corporation or a person that
directly or indirectly controls, is controlled by, or is under common control with, the Corporation), of beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) of securities possessing more than 50% of the total combined voting
power of the Corporation’s outstanding securities pursuant to a tender or exchange offer made directly to the Corporation’s stockholders. 
  
 C. Code shall mean the Internal Revenue Code of 1986, as amended. 
  
 D. Common Stock shall mean the Corporation’s common stock. 
  
 E. Corporation shall mean Buy.com Inc., a Delaware corporation,
or the successor to all or substantially all of the assets or voting stock of Buy.com Inc. which has assumed the Plan. 
  
 F. Discretionary Option Grant Program shall mean the discretionary option grant program in effect under Article 2 of the Plan. 

 
 G. Employee shall mean an individual who is in the employ of
the Corporation (or any Parent or Subsidiary), subject to the control and direction of the employer entity as to both the work to be performed and the manner and method of performance. 
  
 H. Exchange Act shall mean the Securities Exchange Act of 1934, as amended. 
  
 I. Exercise Date shall mean the date on which the option shall
have been exercised in accordance with the applicable option documentation. 
  

 A-1 

 J. Expiration Date shall mean the close of business at the Corporation’s headquarters
on the date the option or SAR expires as set forth in notice of stock option grant or in the SAR agreement. 
  
 K. Fair Market Value per share of Common Stock on any relevant date shall be determined in accordance with the following provisions:

  
 (i) If the Common Stock is at the time traded
on the Nasdaq Stock Market, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question, as such price is reported by the National Association of Securities Dealers on the Nasdaq Stock Market and
published in The Wall Street Journal. If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.

  
 (ii) If the Common Stock is at the time
listed on any stock exchange, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question on the stock exchange determined by the Plan Administrator to be the primary market for the Common Stock,
as such price is officially quoted in the composite tape of transactions on such exchange and published in The Wall Street Journal. If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value
shall be the closing selling price on the last preceding date for which such quotation exists. 
  
 (iii) If the Common Stock is at the time neither listed on any stock exchange or the Nasdaq Stock Market, then the Fair Market Value shall
be determined by the Plan Administrator after taking into account such factors as the Plan Administrator shall deem appropriate but shall be determined without regard to any restrictions other than a restriction which, by its term, will never lapse.

  
 (iv) For purposes of same day sales, the Fair
Market Value shall be deemed to be the amount per share for which the shares of Common Stock were sold. 
  
 L. Incentive Option shall mean an option that satisfies the requirements of Code Section 422. 
  
 M. Involuntary Termination shall mean: 
  
 (i) such individual’s involuntary dismissal or
discharge by the Corporation (or any Parent or Subsidiary) for reasons other than Misconduct, or 
  
 (ii) such individual’s voluntary resignation within 60 days following (a) a change in his or her position with the Corporation
(or any Parent or Subsidiary) which materially reduces his or her duties and responsibilities, (b) a reduction in his or her base salary by more than 15%, unless the base salaries of all similarly situated individuals are reduced by the
Corporation (or any Parent or Subsidiary) employing the individual or (c) a relocation of such individual’s place of employment by more than 50 miles, provided and only if such change, reduction or relocation is effected without the
individual’s written consent. 
  

 A-2 

 N. Misconduct shall mean (i) the commission of any act of fraud, embezzlement or
dishonesty by Optionee or Participant, (ii) any unauthorized use or disclosure by such person of confidential information or trade secrets of the Corporation (or any Parent or Subsidiary), or (iii) any other intentional misconduct by such
person adversely affecting the business or affairs of the Corporation (or any Parent or Subsidiary) in a material manner; provided, however, that if the term or concept has been defined in an employment agreement between the Corporation and
Optionee or Participant, then Misconduct shall have the definition set forth in such employment agreement. The foregoing definition shall not in any way preclude or restrict the right of the Corporation (or any Parent or Subsidiary) to discharge or
dismiss any Optionee, Participant or other person in the Service of the Corporation (or any Parent or Subsidiary) for any other acts or omissions but such other acts or omissions shall not be deemed, for purposes of the Plan, to constitute grounds
for termination for Misconduct. 
  
 O. Non-Statutory
Option shall mean an option that does not qualify as an Incentive Option. 
  
 P. Optionee shall mean any person to whom an option is granted pursuant to the Plan. 
  
 Q. Parent shall mean any corporation (other than the Corporation) in an unbroken chain of corporations ending with the Corporation, provided
each corporation in the unbroken chain (other than the Corporation) owns, at the time of the determination, stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.

  
 R. Participant shall mean any person who is
issued shares of Common Stock under the Stock Issuance Program. 
  
 S. Permanent Disability or Permanently Disabled shall mean the inability of Optionee or Participant to engage in any substantial gainful activity by reason of any medically determinable physical or mental impairment which can
be expected to result in death or has lasted or can be expected to last for a continuous period of twelve months or more. However, solely for purposes of the grants or issuances to non-Employee directors, Permanent Disability or Permanently Disabled
shall mean the inability of such Board member to perform his or her usual duties as a director by reason of any medically determinable physical or mental impairment expected to result in death or to be of continuous duration of twelve months or
more. 
  
 T. Plan shall mean this Buy.com Inc. 2005
Equity Incentive Plan. 
  
 U. Plan Administrator
shall mean the particular entity, whether the Primary Committee, the Board or the Secondary Committee, which is authorized to administer the Discretionary Option Grant and Stock Issuance Programs with respect to one or more classes of eligible
persons, to the extent such entity is carrying out its administrative functions under those programs with respect to the persons under its jurisdiction. 
  
 V. Plan Effective Date shall mean the date the Corporation and the underwriters execute the underwriting agreement for the
Corporation’s initial public offering. 
  

 A-3 

 W. Predecessor Plan shall mean the Buy.com Inc. 2002 Stock Option/Stock Issuance Plan, as
such plan is in effect immediately prior to the Plan Effective Date. 
  
 X. Primary Committee shall mean the Compensation Committee comprised of one or more Board members designated by the Board to administer the Discretionary Option Grant and Stock Issuance Programs. To obtain the benefits of
Rule 16b-3, there must be at least two members on the Primary Committee and all of the members must be “non-employee” directors as that term is defined in the Rule or the Board must approve the grants. To be exempt from the one
million dollar compensation deduction limitation of Section 162(m), there must be at least two members on the Primary Committee and all of the members must be “outside directors” as that term is defined in Code Section 162(m).

  
 Y. Proxy Contest shall mean a change in
ownership or control of the Corporation effected through a change in the composition of the Board over a period of 36 consecutive months or less such that a majority of the Board members ceases, by reason of one or more contested elections for Board
membership, to be comprised of individuals who either (i) have been Board members continuously since the beginning of such period or (ii) have been elected or nominated for election as Board members during such period by at least a
majority of the Board members described in clause (i) who were still in office at the time the Board approved such election or nomination. 
  
 Z. Secondary Committee shall mean a committee of one or more Board members appointed by the Board to administer the Discretionary Option
Grant and Stock Issuance Programs with respect to eligible persons other than Section 16 Insiders. 
  
 AA. Section 16 Insider shall mean an executive officer or director of the Corporation or the holder of more than 10% of a registered
class of the Corporation’s equity securities, in each case subject to the short-swing profit liabilities of Section 16 of the Exchange Act. 
  
 BB. Service shall mean the performance of services for the Corporation (or any Parent or Subsidiary) by a person in the capacity of an
Employee, a member of the board of directors or an independent contractor, except to the extent otherwise specifically provided in the documents evidencing the option grant or stock issuance. 
  
 CC. Stock Appreciation Rights Program shall mean the Stock Appreciation
Rights Program in effect under Article 4 of the Plan. 
  
 DD.
Stock Issuance Agreement shall mean the agreement entered into by the Corporation and Participant at the time of issuance of shares of Common Stock under the Stock Issuance Program. 
  
 EE. Stock Issuance Program shall mean the stock issuance
program in effect under Article 3 of the Plan. 
  
 FF.
Subsidiary shall mean any corporation (other than the Corporation) in an unbroken chain of corporations beginning with the Corporation, provided each corporation (other than the last corporation) in the unbroken chain owns, at the time
of the determination, stock 

  

 A-4 

 
possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations in such chain. 
  
 GG. 10% Stockholder shall mean the owner of stock (after taking
into account the constructive ownership rules of Section 424(d) of the Code) possessing more than 10% of the total combined voting power of all classes of stock of the Corporation (or any Parent or Subsidiary). 
  

 A-5Licensing and Supply Agreement, dated October 31, 2005

 EXHIBIT 10.1 
  
 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote such ommissions.

  
 LICENSING AND SUPPLY AGREEMENT 
  
 THIS LICENSING AND SUPPLY AGREEMENT (this “Agreement”),
effective as of this 31st day of October, 2005 (the “Effective Date”), is by and among GTC Biotherapeutics, Inc., a corporation organized under the laws of the Commonwealth of Massachusetts with its principal offices at 175 Crossing
Boulevard, Suite 410, Framingham, Massachusetts 01702 (“GTC”), and ATIII LLC, a limited liability company organized under the laws of the State of Delaware having its principal place of business at 175 Crossing Boulevard, Framingham,
Massachusetts 01702 which is a wholly owned (100%) subsidiary of GTC, (“ATIII LLC”), and LEO Pharma A/S, a corporation organized under the laws of Denmark, with its principal offices at Industriparken 55, DK-2750 Ballerup, Denmark
(“LEO”). LEO, ATIII LLC and GTC may be referred to herein individually as a “Party” or collectively as the “Parties.” 
  
 RECITALS 
  
 WHEREAS, GTC enjoys the full right and interest in and to GTC’s Intellectual Property Rights, Trademarks and Technical Information (as
hereinafter defined); and 
  
 WHEREAS, LEO has substantial
knowledge, experience and expertise in marketing and selling therapeutic drugs in the Territory; and 
  
 WHEREAS, GTC desires to grant to LEO an exclusive license (even as to GTC) in the Territory under GTC’s Intellectual Property Rights,
Trademarks and Technical Information for purposes of this Agreement; and 
  
 WHEREAS, GTC desires to supply LEO with the Product in the Territory on an exclusive basis (even as to GTC), and LEO desires to accept such appointment; and 
  
 WHEREAS, GTC desires LEO to be the holder of the Marketing
Authorization of the Product in the Territory; and 
  
 WHEREAS, the Parties intend to cooperate in the expansion of indications for the Product through clinical trials, regulatory approval, manufacturing, sales and marketing; 
  
 NOW, THEREFORE, in consideration of the foregoing and the mutual terms, conditions and agreements set forth herein,
the Parties hereby agree as follows: 
  
 1. DEFINITIONS 
  
 As used in this Agreement, the singular includes the plural and the plural
includes the singular, wherever so required by fact or context. Titles used in the Articles hereof shall be only for convenience and shall not be regarded as part of this Agreement. Schedule shall mean any schedule to this Agreement, each of them
being made a part hereof. As used in this Agreement, and unless otherwise provided, the following terms shall have the meanings specified below. Certain other capitalized terms are defined elsewhere in this Agreement. 
  
 CONFIDENTIAL 

 A reference in this Agreement to GTC shall also include a reference to ATIII LLC and a reference to ATIII LLC in this
Agreement shall also include a reference to GTC as the two Parties shall be treated as one legal entity in all aspects in this Agreement. Unless the prior written consent of LEO is obtained ATIII LLC shall for the term of this Agreement remain 100%
owned by GTC. 
  
 “Adverse Event” (AE) shall mean
any untoward medical occurrence in a patient administered a medicinal product and which does not necessarily have to have a causal relationship with this treatment as per the applicable ICH guidelines. An adverse event can therefore be any
unfavorable and unintended sign (for example, an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to this medicinal product. 
  
 “Adverse Drug Reaction” (ADR) shall mean noxious and
unintended responses to a medicinal product, as established by regional regulations, guidance, and practices. 
  
 “Affiliate(s)” shall mean with respect to any Party, any corporation, partnership or other business entity that controls, is controlled
by, or is under common control with such Party. A corporation, partnership or other entity shall be regarded as in control of another corporation, partnership or entity if it owns or directly or indirectly controls at least fifty percent
(50%) of the voting stock or other ownership interest of the other corporation, partnership or entity or if it possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of the corporation,
partnership or other entity or the power to elect or appoint at least fifty percent (50%) of the members of the governing body of the corporation, partnership or other entity. The term “control” means the possession, directly or
indirectly, of the power to direct or cause the direction of the management and policies of an entity, whether through the ownership of voting securities, by contract or otherwise. 
  
 “Approval” means receipt of approval of an MAA for the Product from the European Commission, or approvals
from other Regulatory Authorities in the Territory. 
  
 “Best efforts” shall mean the level of effort which, consistent with the exercise of prudent scientific and business judgment is diligently applied by the relevant Party to its other therapeutic products at a similar stage
of development and with similar commercial potential. 
  
 “cGMP” means the regulatory requirements for current good manufacturing practices promulgated by (as applicable) the FDA, the European Commission or other applicable Regulatory Authority. 
  
 “Commercial Sale” means any commercial arms-length Sale of
Product by LEO or any of its Affiliates to a Third Party (other than in any non-commercial patient use) following Regulatory Approval and, as applicable, Reimbursement Approval of the Product in the applicable jurisdiction. 
  
 “Cost of Goods” means the direct variable costs and direct
fixed costs associated with the manufacture of the Product ex-factory. Direct variable costs shall be deemed to be the 

  

 2 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 
cost of labor, raw materials, supplies and other resources directly consumed in the manufacture of such Product. Direct fixed costs shall be deemed to be the
cost of facilities, utilities, insurance, equipment depreciation, allocable manufacturing administration, and other fixed costs directly related to the manufacture of such Product. Direct fixed costs shall be allocated to such Product based upon the
proportion of such costs directly attributable to support of the manufacturing process for such Product. If a facility (not solely dedicated to the manufacture of the Product) is used to manufacture products for other programs of a Party, direct
fixed costs shall be allocated in proportion to the actual use in days to manufacture the Product divided by the total number of days available on an annual basis (365). Except as otherwise provided in this Agreement, all cost of goods
determinations made hereunder shall be made in accordance with US GAAP. 
  
 “CTD” means the Common Technical Document format (as defined by ICH) used to prepare an application to be filed with the FDA, the EMEA, or other applicable Regulatory Authorities after completion of human clinical trials to
obtain marketing approval for the Product in the applicable jurisdiction. 
  
 “Effective date” shall mean the 31st day of October 2005. 
  
 “EMEA” means the European Medicines Agency or any successor agency with responsibilities comparable to the European Medicines Agency.

  
 “Event of Default” means any failure of the
Defaulting Party (as defined below) to cure any breach or default of any material covenant (including failure to perform) or agreement contained in this Agreement within a period of ************ days after receipt by the Defaulting Party of notice
of such breach or default from the other Party. 
  
 “Defaulting Party” shall mean the Party to which such an event relates. 
  
 “************”. 
  
 “FDA” means the United States Food and Drug Administration or any successor agency with responsibilities comparable to the United States
Food and Drug Administration. 
  
 “Field” means
all therapeutic, diagnostic, prophylactic and monitoring applications of the Product in humans. 
  
 “GAAP” means United States generally accepted accounting principles, consistently applied. 
  
 “GTC Intellectual Property Rights” means those patents,
patent applications and in-licensed rights necessary to achieve the objectives of the Program and which are set forth in Schedule B herein, including but not limited to divisional applications, continuation applications, continuation-in-part
applications and any patent issued on said applications and any reissues, extensions or Supplementary Protection Certificates granted on such patents. 
  
 “HD Indication” means the Product as indicated in patients with congenital antithrombin deficiency for the prophylaxis of deep vein
thrombosis and thromboembolism in clinical risk situations (especially during surgery or during the peri-partum period), in association with heparin if indicated. 
  

 3 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 “ICH” means the International Conference on Harmonization of Technical Requirements
for Registration of Pharmaceuticals for Human Use. 
  
 “Initial Term” means the period beginning on the Effective Date and continuing until the ************ anniversary of the date of Approval of the Product with the European Commission for the HD Indication, unless terminated
earlier in accordance with the provisions of Article 13. 
  
 “Insolvency Event” means: (i) filing a petition in voluntary bankruptcy or making an assignment for the benefit of creditors or consenting to the appointment of a receiver of all or any substantial part of the property
of a Party, or filing a petition to take advantage of any debtors act; (ii) the commencement against a Party of any case, proceeding or other action seeking the adjudication of such Party as bankrupt by a court of competent jurisdiction or the
appointment by such a court of a trustee or receiver or receivers of such Party or of all or any substantial part of the property of such Party upon the application of any creditor in any insolvency or bankruptcy proceeding or other creditors suit,
which case, proceeding or other action is not dismissed within ************ days after its commencement; or (iii) any event or act analogous to any of these. 
  
 “Invention” mean an invention conceived and reduced to practice by GTC, LEO or GTC and LEO jointly during
the course of conducting the GTC Development Activities, the LEO Development Activities or development activities agreed jointly from time to time during the Term (whether or not patentable) necessary or useful to discover, develop, make, use or
sell a Product. 
  
 “MAA” means a marketing
authorization application or similar application filed with a Regulatory Authority after completion of human clinical trials to obtain marketing approval for the Product in the applicable jurisdiction. 
  
 “MedDRA” means the Medical Dictionary for Regulatory
Activities Terminology developed under the auspices of ICH. 
  
 “Net Sales” means the gross invoiced Sales of LEO within the Territory (“Sale” to be defined as in the definition below) of the Product billed to independent Third Party customers (i.e. ex LEO Sales) less, to the
extent such amounts are included in the gross invoiced sales price, the actual amount of: (i) freight and insurance costs incurred in transporting such Product to such customers; (ii) quantity, cash and other trade discounts actually
allowed and taken; (iii) customs duties, surcharges and taxes and other governmental charges incurred in connection with the exportation or importation of such Product in final form; (iv) amounts repaid or credited by reason of rejections
(due to Product spoilage, damage, expiration or useful life or otherwise) or retroactive price reductions; (v) amounts incurred resulting from governmental mandated rebate or discount programs; and (vi) Third Party rebates and charge backs
actually allowed and taken, including without limitation hospital buying group charge backs, hospital buying group/group purchasing organization administration fees or managed care organization rebates. The amount of Net Sales accrued for any period
shall be determined on the basis of Sales recorded in such period in accordance with the Danish Act on Commercial Enterprises’ Presentation of Financial Statements, etc. (Årsregnskabsloven). 
  

 4 

 “Other Study” means a study relating to the Product that cannot or will not be used for
registration purposes. 
  
 “Patent Rights” means:
(a) an unexpired patent which has not been held invalid or unenforceable by a court of competent jurisdiction from which no appeal can be taken or has been taken within the required time period, including without limitation any substitution,
extension, registration, confirmation, reissue, re-examination, renewal or any like filing thereof; and (b) pending patent applications, including without limitation any provisional, converted provisional, continued prosecution application,
continuation, divisional or continuation-in-part thereof. 
  
 “Product” shall mean a product that is a pharmaceutical preparation for human use incorporating antithrombin alfa as its active pharmaceutical ingredients. 
  
 “Program” means the marketing, Sales, manufacturing and clinical development activities described in this
Agreement. 
  
 “Registration Study” means a
clinical or non-clinical trial that can be used to file for or extend an MAA. 
  
 “Regulatory Approval” means receipt of approval of a MAA or for revision of a MAA for any Product issued by any Regulatory Authority in the Territory that is required for the commercial sale of such
Product in the applicable country or region within the Territory. Regulatory Approval shall not include Reimbursement Approval. 
  
 “Regulatory Authority” means the regulatory authority of any country or region in the Territory with responsibility for approving the
Product for sale in such country. 
  
 “Reimbursement
Approval” means the approval of the Reimbursement Price for any Product as established by a Reimbursement Authority in the Territory. Reimbursement Approval shall not include Regulatory Approval. 
  
 “Reimbursement Authority” means the regulatory authority of
any country in the Territory with responsibility for setting the Reimbursement Price in such country. 
  
 “Reimbursement Price” means the reimbursement price for the Product established, approved and as modified from time to time by the
Reimbursement Authority in the applicable country. 
  
 “Responses to Medicinal Product” means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility (as per ICH guideline E2A). A reaction, in contrast to an event, is
characterized by the fact that a causal relationship between the drug and the occurrence is suspected. For regulatory reporting purposes, if an event is spontaneously reported, even if the relationship is unknown or unstated, it meets the definition
of an adverse event. 
  

 5 

 “Sale(s)” (or “Sell” or “Sold”) means any sale,
assignment, transfer, conveyance or other disposition of the Product by LEO or any of its Affiliates to a Third Party (other than for quality assurance or control purposes). For the sake of clarification, a sale, assignment, transfer, conveyance or
other disposition of the Product by LEO to any of its Affiliates shall not be considered a Sale for purposes of this definition. 
  
 “Second Indication” means the first indication for the Product other than the HD Indication for which the Parties develop the Product for
use in the Territory or seek Regulatory Approval for the Product in the Territory. 
  
 “Serious Adverse Event/Adverse Drug Reaction” means in accordance with the applicable ICH guidelines, a serious adverse event or drug reaction is any untoward medical occurrence that at any dose:

  

	 	•	 	results in death 

  

	 	•	 	is life threatening (Note: The term “life threatening” in the definition of “serious” refers to an event/reaction in which the patient was at risk of death at
the time of the event/reaction; it does not refer to an event/reaction which hypothetically might have caused death if it were more severe) 

  

	 	•	 	requires inpatient hospitalization or results in prolongation of existing hospitalization 

  

	 	•	 	results in persistent or significant disability/incapacity 

  

	 	•	 	is a congenital anomaly/birth defect 

  

	 	•	 	results in other medically important conditions. 

  
 “Sharing Percentage” means, as to each party, the percentage of total worldwide sales of the Product that was represented by the Net
Sales of the Product in its respective territory (with the definition of Net Sales to be deemed appropriately modified in the case of LEO to cover the Sales of LEO, its Affiliates, distributors, agents and other third parties engaged in the Sales on
behalf of LEO in the LEO Territory) during the immediately preceding calendar year. 
  
 “Specifications” means the set of criteria for acceptance/rejection of bulk drug substance or the Product, as the case may be, when tested by methods described in the MAA (or equivalent), as approved
by the Regulatory Authorities and any additional specifications as are mutually agreed upon by the Parties hereto in writing. 
  
 “Technical Information” means all information in the possession of GTC and/or its affiliates regarding preclinical,
chemical-pharmaceutical and clinical data or other scientific information (including specifications, master batch records, analytical methods including validation protocols and the drug master file), trade secrets and know-how or uses for the
Product including, but not limited to, marketing know-how or uses for the Product in the possession of GTC regarding the Product necessary for LEO to fulfill its obligations under this Agreement. 
  

 6 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 “Territory” means the countries and their respective territories and possessions
listed in Schedule A. 
  
 “Third Party” means any
person other than a Party or its Affiliates. 
  
 “Trademarks” means GTC’s trademarks, service marks, trade names, trade dress and logos used on or in connection with the identification or marketing of the Product, including those listed in Schedule B, hereto (as the
same may be amended and supplemented from time to time by GTC as agreed and approved by the Coordinating Committee). 
  
 “Unit” means one international unit (IU) of antithrombin as measured by a thrombin inhibition assay consistent with the European
Pharmacopoeia. 
  
 “Waste” shall mean a
“hazardous substance” (as defined in the Federal Comprehensive Response, Compensation and Liability Act, as amended) and “Waste” (as defined in the Federal Resource Conservation and Recovery Act, as amended), and includes waste
of any kind, including without limitation both routine process waste and by-product which are disposed of, and the foreign equivalents of such terms as defined by the relevant regulatory authorities of countries other than the United States.

  
 2. LICENSE GRANT and APPOINTMENT 
  
 2.1 Appointment and Grant. GTC and ATIII LLC hereby grants LEO, and
LEO accepts from GTC and ATIII LLC, an exclusive license (even as to GTC) within the Field in the Territory with the right to sublicense within the Territory under the GTC Intellectual Property Rights, Trademarks and Technical Information owned by,
or licensed to, GTC and ATIII LLC to import, store, package, label, use, develop, register, sell, and offer for sale, distribute and have imported the Product in the Field and in the Territory. LEO shall undertake to inform GTC of such sublicenses
within ************ days prior to entering into an agreement, and give GTC an opportunity to comment and ensure that such sub licensees adhere to the conditions set out in this Agreement to the extent necessary to protect the proprietary rights of
GTC and ATIII LLC pursuant to this Agreement. In no other respect, other than as set out in this Agreement, may LEO or its sublicensees practice GTC Intellectual Property Rights, Trademarks and Technical Information. 
  
 3. COORDINATING COMMITTEE 
  
 3.1 Establishment of the Coordinating Committee. Promptly after the
Effective Date, the Parties shall establish a committee consisting of personnel from GTC and LEO with expertise in clinical development, manufacturing, regulatory affairs, reimbursement, sales, marketing, intellectual property and finance (the
“Coordinating Committee”). The Coordinating Committee shall be comprised of such number of members as the Parties may determine from time to time, except that each Party shall always have at least three (3) member representatives
thereon. A Party may change one or more of its representatives to the Coordinating Committee at any time. Members of the Coordinating Committee may be replaced at any meeting by another member of the Coordinating Committee or by a deputy. Both
Parties shall have equal voting rights notwithstanding the number of representatives of each present at any meeting of the 

  

 7 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 
Coordinating Committee. Without limiting the generality of the foregoing, the Coordinating Committee shall decide on the following reserved matters:

  
 (a) clinical issues: both Parties shall agree on the
development plan and overall strategy for development of the Product both within and outside of the Territory respectively to the extent it may negatively impact the Territory. The Parties will also agree to discuss the obligation of LEO to initiate
the process of obtaining scientific advice from the EMEA relating to the clinical development of the Product for the Second Indication, but agree that such advice will be sought within ************ days following execution of this Agreement. Budgets
for jointly funded trials shall be approved by the Coordinating Committee. 
  
 All potential investigator sponsored studies both within and outside of the Territory will be subject to review of the Coordinating Committee to the extent it may negatively impact the Territory. 
  
 (b) non-clinical issues: both Parties shall agree on the development
plan and overall strategy for development of the Product, both within and outside of the Territory respectively. Budgets for jointly funded Registration Studies shall be approved by the Coordinating Committee and paid for, cf. Article 6.1 (b).

  
 (c) manufacturing/quality issues: both Parties shall
agree on any issues related to changes in the manufacturing and/or quality that can affect the registration file. 
  
 The Coordinating Committee shall review on the following matters: 
  
 (d) regulatory affairs: both Parties shall review all issues or changes to be made to the regulatory files within the Territory, and outside the
Territory where such changes can affect the registration within the Territory. 
  
 (e) review such actions as the Parties may decide are appropriate to further the development of the Product such as review of scientific publications, Investigator’s Brochure and medical information
provided to healthcare professionals both within and outside of the Territory respectively. 
  
 (f) review the Sales and Marketing plan for the Product both within and outside the Territory. 
  
 (g) review and discuss new indications for the Product. 
  
 3.2 Operation of the Coordinating Committee. The Coordinating Committee shall meet at such times and places as it may determine but, in any event,
it shall meet within ************ days after the Effective Date and at least once during each calendar quarter after the Effective Date. If the Coordinating Committee does not determine to meet elsewhere, its meetings shall alternate locations
between the offices of GTC and LEO, with the first meeting to be held at LEO. The Coordinating Committee may meet in person or by video or telephone conference (if practical), and individual members may participate in any of the foregoing ways. All
costs of participation by each member in the activities of the Coordinating Committee shall be borne by the Party appointing such member. LEO and GTC shall each designate one (1) of 

  

 8 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 
their respective representatives on the Coordinating Committee to act as Co-Chair. The Coordinating Committee shall appoint a secretary each year that shall
maintain the records of the Coordinating Committee and shall keep minutes of the meetings thereof. The records and minutes shall be maintained in English. The secretary shall distribute minutes to all members of the Coordinating Committee at the
same time not later than two weeks following said meeting. The secretary shall be provided on a rotating basis each year by GTC and LEO (initially to be selected by LEO). Moreover, each Party shall appoint one person as the point person for
communications between the Parties regarding on-going progress hereunder. 
  
 3.3 Decision-Making. The Coordinating Committee will strive to reach consensus on matters over which it has authority. Subject to the foregoing and except as otherwise provided herein, if, at a meeting of the
Coordinating Committee, the Coordinating Committee is unable to reach consensus on a particular issue, the members of the Coordinating Committee will make good faith efforts to resolve such issue over the next ************ days. If after
************ days such effort is unsuccessful, the Parties will refer any such dispute to two duly appointed senior officers of the Parties, one from GTC the other from LEO (e.g. the Chief Financial Officer, of GTC and the Head of Research and
Development, of LEO for attempted resolution by good faith negotiations. Either Party may reject a proposal which the Party can demonstrate by objective financial, economic or regulatory data is likely to have a negative impact on the Party. If
after a further period of ************ days the appointed officers of the Parties are still unable to solve the matter successfully, the Parties will refer the still pending dispute to the respective CEOs of the Parties for a final attempted
resolution by good faith negotiations. In case the CEOs are also unable to reach a solution the matter may be referred to arbitration as set out below in Article 14 of the Agreement. 
  
 3.4 Limitations of Joint Steering Committee Powers. The Coordinating Committee will have only such powers as are
specifically delegated to it in this Agreement, and will have no power to amend this Agreement or waive a Party’s rights or obligations under this Agreement. 
  
 4. MANUFACTURE AND SUPPLY OF PRODUCT 
  
 4.1 Manufacture of Product 
  
 The Parties agree to establish the operating procedures for forecasting, ordering, production scheduling and inventory management to meet the principles
set out in Schedule D within ************ days following the execution of this Agreement and in accordance with the principles set forth in this Article 4. 
  
 (a) Representations, Warranties and Covenants of GTC. GTC or its subcontractors shall manufacture the Product in accordance with cGMP and the
Specifications and deliver, within designated timeframes and agreed upon quantities, at the expense of LEO, the Product to LEO at such location or locations, specified by LEO in accordance with orders placed by LEO. Without limiting the foregoing,
GTC shall and shall cause its subcontractors to perform, or have performed, at its own expense, each of the following activities with respect to Product to be supplied to LEO or intended for use by LEO: 
  
 (i) register and for the term of this Agreement undertake to maintain a
valid registration of the GTC manufacturing facility (or, in GTC’s sole discretion, such other 

  

 9 

 
suitable facility as GTC may designate, including a Third Party manufacturing facility) with the relevant and appropriate Regulatory Authorities as a
facility performing manufacturing operations for biological products and prepare site master files as required by applicable laws and regulations. GTC shall not make changes or take actions which will require LEO to amend any Registration including
but not limited to transfer of any Product to alternative manufacturing facilities or changes in or replacement of equipment or a change in the Specifications, without the prior written consent of LEO via the Coordinating Committee, which consent
shall not be unreasonably withheld; provided that such amendment is for good reason, including a change mandated by a Regulatory Authority, and any costs relating to such change or action shall be at the sole expense of GTC. All other changes
specifically requested by LEO, which are not mandated by a Regulatory Authority, LEO will bear the costs relating to such change or action; 
  
 (ii) validate the production process for the Product to ensure that such process is compliant with cGMP as appropriate in the Territory. All Product
delivered by GTC to LEO hereunder shall have been manufactured using a process that has been validated in accordance with cGMP and has been manufactured in compliance with the Specifications for such Product and with cGMP and all laws with respect
to the manufacture of each Product. 
  
 (iii) handle and store
the Product prior to shipment to LEO as mandated by cGMP to ensure that the raw materials, recipients, packaging articles, intermediate products and the Products are handled and stored under such conditions that the quality of such materials and the
Products manufactured therefrom are not affected; 
  
 (iv) ensure
that each shipment of the Product meets the Specifications and all applicable warranties set forth herein; 
  
 (v) deliver the Product to LEO in accordance with the procedure to be proposed by LEO with the approval of GTC, such approval not to be unreasonably
withheld or delayed; 
  
 (vi) handle, store, treat and dispose of
Wastes generated in the performance of its activities under this Article; 
  
 (vii) comply with all applicable laws and regulations relating to its activities hereunder, including without limitation cGMP; and 
  
 (viii) adopt and assure, if the GTC manufacturing facilities are being used to manufacture material other than the Product,
that a standard operating procedure for segregation of the Product and such other materials manufactured has been established in such facilities. 
  
 (ix) supply sufficient quantities of the Product to LEO to satisfy the purchase requirements of LEO. In consideration of the arrangements provided in
this Agreement, GTC agrees that LEO will be treated with “most favored distributor” status in connection with allocation of Product, so that if there is a shortfall of Product as between LEO and a distributor (including GTC) outside the
LEO Territory, GTC will allocate Product in such a manner no less favorable to LEO than a percentage that is equivalent to the current Sharing Percentage of LEO. Failure by GTC to supply sufficient amounts of Product based on the 

  

 10 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 
above forecasting shall not constitute a breach of this Agreement by GTC, provided such inability is caused by an increase in the forecast by more than
************ compared to the previous forecast received from LEO. 
  
 (x) except as otherwise specifically agreed between the Parties in writing, be responsible for procuring all raw materials and other components for each Product. All raw materials and components procured by GTC and used in the Product shall
be tested (by GTC or its third party supplier thereof) to assure that they meet applicable Specifications and quality standards. 
  
 (xi) perform all of the services provided herein in compliance with all environmental laws and shall be solely responsible for all environmental losses
at sites controlled by GTC. GTC shall be solely responsible for implementing and maintaining health and safety procedures for the manufacture, generation, packaging, handling and storage of the raw materials, hazardous materials, Waste, packaging
components and Products as provided herein. Such procedures shall comply with all relevant environmental laws. LEO shall have no responsibility for developing, implementing or overseeing health and safety programs at GTC. 
  
 Subject to the rights and obligations vested in GTC under this Agreement GTC shall be
permitted to contract with one or more Third Parties to perform the manufacturing activities described herein in accordance with the terms hereof. GTC shall be responsible for the performance of its subcontractors under this Agreement. 

 
 (b) Representations, Warranties and Covenants of LEO. LEO shall
and shall cause any subcontractors, to comply with all applicable laws and regulations relating to its activities hereunder, including all requirements of the Regulatory Authorities and cGMP thereunder. 
  
 4.2 Quality Assurance. No later than 2 months after the Effective
date, the Parties shall enter into a QA/QC Agreement substantially in the form of Schedule C. To the extent of any conflict or inconsistency between this Agreement and such QA/QC Agreement, the terms of and conditions of this Agreement shall
control, unless otherwise agreed to in writing by the Parties. 
  
 4.3 Orders and Shipments 
  
 (a) LEO
shall order the Product from GTC, and GTC shall supply the Product to LEO in accordance with the procedures set forth in Schedule D to cover the requirements of LEO for the Product for the performance of clinical trials and sale and distribution
within the Territory. 
  
 (b) The Product supplied for
purposes of commercial Sale shall have a minimum shelf life of ************ from the date of delivery assuming a total of ************ shelf life, however, no less than ************ of the applicable shelf life at time of delivery. The Product
supplied for purposes of Clinical Studies shall have a minimum shelf life ************ from the date of delivery assuming a total of ************ shelf life, however, no less than ************ of the applicable shelf life at time of delivery.

  

 11 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 (c) After delivery LEO shall, within ************ business days, visually inspect the Product
shipment and communicate acceptance or rejection to GTC in writing. The Parties agree that the visual inspection by LEO consists of (i) comparing the applicable order against the documentation accompanying the shipment to verify that the
delivery date, identity, quantity and exterior shipment labelling comply with the order and (ii) visually inspecting the exterior of the Product shipment to verify that the shipment appears to be in good condition. 
  
 (d) If GTC does not agree to any rejection of the Product the Parties
will seek the opinion of an independent laboratory reasonably acceptable to both Parties, whose opinion shall be final and binding. The expenses for such expert opinion shall be borne by the Party shown to be wrong, or, if the expert cannot identify
the responsible Party, then the Parties shall share equally the expenses connected with the expert and the expenses connected with the Products rejected and/or returned. 
  
 (e) Return and Replacement. Any quantities of the Product that are rejected and/or returned by LEO in accordance
with this Agreement whose rejection has been accepted by GTC shall be returned to GTC at the expense of GTC and at the option of LEO (a) shall be replaced by GTC as quickly as possible at GTC’s sole expense and the payment in respect of
such quantities postponed until such replacement quantities are received and accepted by LEO unless GTC is unable to do so, in which case (b) GTC shall refund any amounts paid in respect of such quantities to LEO. 
  
 4.4 Storage. LEO shall store and transport the Product in full
accordance with the applicable rules and regulations in the relevant countries of the Territory, with the guidelines on the Good Distribution Practice - EU guidelines No C63 of 1994 or any current revision and with the instructions given by
GTC, and the national health authorities in the relevant part of the Territory. In all cases, LEO shall comply with all applicable laws, rules and regulations concerning the labeling, packaging, warehousing and distribution of Product. 

 
 4.5 Return of Product. Unless LEO in each separate case in advance
has explicitly accepted to receive such Products, which have passed the date of the minimum required remaining shelf life on the date received by LEO, then LEO may return such Product to GTC, or shall if GTC so desires be transported to a place
designated by GTC for destruction. The destruction is to take place by an organization authorized for this purpose, such organization to issue an official confirmation of the destruction to GTC. All expenses regarding the transportation and/or
destruction of such Product are to be paid by GTC. Upon the aforementioned disposal of the Products, GTC shall not later than ************ days after receipt of the returned Product or notification of the disposal hereof as mentioned above issue a
credit note to LEO in the amount of the actual purchase price paid by LEO for the Products now returned. 
  
 4.6 Payments. LEO will pay GTC for all shipments of Product in accordance with the terms and conditions set forth in Article 8 below. 

 

 12 

 5. OBLIGATIONS OF THE PARTIES REGARDING MANUFACTURING, SALES and CLINICAL DEVELOPMENT OF PRODUCT 
  
 5.1 General Obligations. GTC shall be solely responsible for
obtaining Approval of the Product with European Commission for the HD Indication. GTC shall be responsible for the manufacturing, testing, purification filling and finishing (to naked vials) of the Product. GTC shall be responsible for the conduct
of all non-clinical activities regarding the Product. In the Territory, LEO shall be responsible for additional Product registration (meaning beyond HD) regulatory maintenance, adverse experience reporting, packaging, labeling, storage, marketing
and Sales and distribution of the Product. In addition, LEO shall, with coordination, planning and agreement with GTC through the Coordinating Committee, be primarily responsible, for clinical development and regulatory activities associated with
Registration Studies or Other Studies in the Territory as defined in Article 6. 
  
 For the avoidance of doubt, it is understood that the Coordinating Committee must approve clinical development plans and protocols for Registration Studies as set out in Article 3 above. 
  
 LEO will not commence the clinical development for indications beyond HD
until GTC has obtained Approval of the Product from the European Commission for the HD Indication. 
  
 The cost associated with the non-clinical and clinical development activities shall be split between the Parties based on the guiding principles set out
below in Article 6. 
  
 (a) GTC Development
Activities. GTC will be responsible for undertaking the following overall development activities and will use Best Efforts to perform these: All product quality and non-clinical related issues in respect of the Product. The Coordinating
Committee will monitor GTC’s performance of its obligations and progress towards achieving the goals set forth in the development plans presented to and approved by the Coordinating Committee. 
  
 (b) LEO Development Activities. LEO will be responsible for
undertaking the following overall development activities and will use Best Efforts to perform these: All clinical and safety related issues in respect to the Product in the Territory. The Coordinating Committee will monitor the performance of LEO
regarding its obligations and progress towards achieving the goals set forth in the development plans presented to and approved by the Coordinating Committee. 
  

(c) Following the approval of the Product in the HD Indication by the European Commission, GTC shall, as soon as practical and after Approval
by EMEA and the European Commission, make LEO the holder of the Marketing Authorization for the Product in the HD Indication together with the complete file, including correspondence with Regulatory Authorities in the Territory. LEO shall be
responsible for transfer fees and other administrative fees associated with the maintenance of the MAA. 
  
 5.2 Specific LEO Obligations. LEO hereby agrees (and shall use Best Efforts to impose similar obligations on its distributors and agents within the
Territory) to exercise its Best Efforts to import, label, pack, store, market, sell and distribute the Product for the HD Indication initially (after receipt of the Approval for the HD Indication) and LEO shall have the obligation, to label, market,
sell and distribute the Product for any other indications subsequently approved for inclusion in the Product labeling by the Regulatory Authorities in the Territory. The above shall include: 
  
 (a) promote the sale of the Product in countries in the Territory,
and prepare and disseminate promotional materials and advertising in all relevant local languages 
  

 13 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 (b) diligently progress clinical development through registration studies for additional
indications in the Territory and provide the Coordination Committee with a draft clinical development plan for the ************Indication within ************ days of execution of this Agreement; 
  
 (c) establish and maintain a well-trained sales force for the Product
(together with a well-trained support staff) adequate to service all the customers of LEO and to promote the sale of the Product in the Territory and keep the sales force knowledgeable and fully informed as to the Product, by among other things,
requiring that they attend periodic LEO sponsored training. 
  
 (d) maintain a prompt delivery service compatible with good business practice, the nature of the Product, and the requirements of its customers; 
  

(e) considering the characteristics of the Product, transport and store the Product to preserve the quality of the Product in accordance with
all regulatory filings; 
  
 (f) obtain and maintain all
material licenses, approvals and permits (other than those which must be obtained by GTC) necessary for LEO to perform its obligations under this Agreement; 
  
 (g) notify GTC as soon as practical upon its becoming aware of any material occurrence of disparagement of the Product or infringement of any
rights relating to the Product in the Territory; 
  
 (h)
promptly evaluate Adverse Events to determine if they are Serious Adverse Events and report to GTC any Serious Adverse Events in accordance with the Pharmacovigilance Procedures Agreement set out in Schedule E; 
  
 (j) establish and maintain suitable systems and records (including
lot numbers of the Product sold and the purchasers of the Product) to enable a recall of Product in a timely, efficient and accurate manner and otherwise in accordance with applicable laws and regulations; 
  
 (k) abide by all applicable rules and regulations related to Sales,
marketing, and reimbursement with respect to the Product in the Territory; 
  
 (l) ensure that no Product shipped by it at the time of shipment is adulterated or misbranded as a result of acts or omissions by LEO; 
  
 (m) provide timely and reasonable assistance to GTC to enable GTC to comply with its obligations under this
Agreement, including without limitation by responding to reasonable requests by GTC and providing GTC with reasonable information relating to the Product; and 
  

(n) conduct all regulatory activities necessary to obtain Product registration in all countries in the Territory which are not in the European
Union, where it is commercially viable to do so, and not subject to the initial approval by the European 

  

 14 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 
Commission for the HD indication. For this purpose GTC shall provide LEO with all of its relevant data regarding the Application for the HD Indication for
the Product as submitted to FDA. Within ************days of execution of this Agreement, LEO will provide a plan and projected timeline for obtaining regulatory approvals in EMEA countries, where LEO has its own Affiliates. In case LEO within two
years after Approval of the ************ indication has not applied for an MAA for that indication or is seeking to actively market the Product in specific countries within the Territory then GTC shall have the option to enter such countries on a
semi-exclusive basis. 
  
 (o) maintain adequate control
over the physical security of the Product, including, but not limited to controls necessary to prevent potential distribution or sale of Product outside of the Territory,. 
  
 (p) agree, after an Approval of the Product with the European Commission for the ************ Indication has been
obtained, and subject to further negotiations with GTC, on an annual minimum royalty for three consecutive calendar years at a time to take effect from the second calendar year following said Approval of the Product with the European Commission for
the ************ Indication. The annual minimum royalty shall be agreed upon by the Parties and subsequently monitored via the Coordinating Committee. The first time an annual minimum royalty is agreed shall be after realization of the first full
calendar year of sale of the Product in the ************ Indication. 
  
 (q) Except to the extent resulting from (i) the activity or inactivity of GTC (including, without limitation, by GTC failing to timely Manufacture or supply Product to LEO or failing to comply with its obligations pursuant to
this Agreement), (ii) a Force Majeure Event, (iii) the Product being voluntarily or involuntarily withdrawn from the market, or (iv) the Sale of the Product infringes the rights of a patent or trademark or other intellectual property
held by a third party, if during the specific year , the actually paid up royalties in accordance with Article 8 does not equal an amount corresponding to the agreed annual minimum royalty for any calendar year in the Territory then (a) LEO
shall pay to GTC an amount equal to the difference between (i) the annual minimum royalty agreed for that calendar year and (ii) the amounts already paid by LEO under Article 8 with respect to such calendar year, with such payments to be
made simultaneously with the payments due LEO under Article 8 in respect of the fourth quarter of such calendar year, and (b) if LEO does not make such payments when due, GTC shall have the right to convert the licenses in Article 2.1 to
non-exclusive licenses by written notice to LEO, if LEO has not cured such failure within ************ days following receipt of such notice. In addition, subject to the exceptions set forth in the first sentence of this Article 5.2 (q), in the
event that the total annual Sales volume post approval of the ************ indication is not achieved in the Territory for three (3) consecutive calendar years, GTC shall have the right to convert the licenses in Article 2.1 to
semi–exclusive licenses (meaning only GTC and its distributors and LEO and its distributors can act within the Territory) by written notice to LEO. 
  
 5.3 First Sale. LEO shall commence the marketing, sale and distribution of the Product in each country within the Territory where it is
commercially viable to do so, as soon as commercially reasonable following the date on which the Regulatory Approval and Reimbursement Approval, as applicable, for the Product is granted in such country to the extent consistent with then current
supply levels of Product satisfying the Specifications. 
  

 15 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 5.4 Restrictions. Notwithstanding the above and to the extent allowed by law within the
Territory, LEO agrees that during the Term of this Agreement it shall not sell, co-promote or market, by itself or in cooperation with a Third Party, any plasma derived or recombinant Antithrombin product which is competitive to the Product. For the
avoidance of doubt, LEO may market other products within the areas of ************ and anticoagulation, including (but not limited to) heparin and low molecular weight heparin. 
  
 LEO shall refrain from seeking customers, establishing any branch and/or maintaining any distribution depot regarding the Products outside
the Territory and shall take legal measures to assure that no Product is imported into the United States or to any other country outside the Territory from any country within the Territory, for any purpose. GTC has neither expressly nor implicitly
given its consent to the storage, distribution, promotion, marketing and sale of the Product outside the Territory, and GTC expressly reserves its right to enforce Trademarks and its GTC Intellectual Property Rights in the Product and to prevent the
importation, storage, distribution, promotion, marketing and sale of the Product in any jurisdiction outside the Territory to the extent such prevention is legally possible. 
  
 GTC shall during the Term of this Agreement refrain from seeking customers, establishing any branch and/or maintaining any distribution
depot regarding the Product within the Territory. Furthermore, GTC shall during the Term of this Agreement refrain from selling, co-promoting or marketing, (except for the purposes of conducting clinical trials in the HD Indication) by itself or in
cooperation with a Third Party, any plasma derived or any recombinant antithrombin product or combination product incorporating the Product which is competitive to the Product. Notwithstanding the aforementioned GTC shall grant to LEO a right of
first negotiation at similar terms as will be offered to a third party with respect to any combination products incorporating the Product, and analogs or derivatives of the Product that GTC develops.. If LEO chooses not to assume responsibility for
such combination products, analogs or derivatives or if the Parties are unable to negotiate reasonable terms, then GTC shall have the right to market such combination products, analogs or derivatives. 
  
 In case of termination of this Agreement by LEO for Cause as mentioned below in Article 13.3
(a), GTC, its Affiliates and/or successors shall not sell, co-promote or market, by itself or in cooperation with a Third Party, any plasma derived or any recombinant antithrombin product or combination product incorporating the Product, including
GTC’s antithrombin alfa, in the Territory for up to ************ years after termination. 
  
 5.5 Specific GTC Obligations. GTC hereby agrees to exercise its Best Efforts to do the following: 
  
 (a) ensure that all Product shipped hereunder at the time of shipment is not adulterated or misbranded as a result of acts or omissions by GTC;

  
 (b) obtain and maintain in its name or in the name of
any of its Affiliates all material licenses, approvals and permits (other than those which must be obtained by LEO) for the Product necessary for GTC to perform fully its obligations under this Agreement; 
  
 (c) provide LEO, from time to time, with data, analyses, studies and
other information available to GTC at any time during the Term which the Coordination Committee believes will assist LEO in its brand planning and marketing activities for the Product in the Territory; 
  

 16 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 (d) promptly evaluate Adverse Events to determine if they are Serious Adverse Events for the
Product, report to LEO any Serious Adverse Events in accordance with the Pharmacovigilance Procedures Agreement set out in Schedule E; 
  
 (e) provide timely and reasonable assistance to LEO to enable LEO to comply with its obligations under this Agreement, including without
limitation by responding to reasonable requests by LEO and providing LEO with information relating to the Product reasonably available to GTC; and 
  
 (f) establish and maintain suitable systems and records to enable a recall of Product in a timely, efficient and accurate manner and otherwise in
accordance with applicable laws and regulations; 
  
 (g)
promptly after execution of this Agreement provide LEO with relevant information with respect to GTC’s MAA to assist LEO in making appropriate filings in the Territory. 
  
 (h) provide LEO with an Approved Product for HD in the European Union. 
  
 (i) provide LEO with all of GTC’s relevant data regarding the
Application for the HD Indication for the Product as submitted to FDA. 
  
 5.6 Support for New Indications. Either Party shall have the right, but not the obligation, to conduct clinical trials for the Product for a Second, and subsequent, Indication(s) in the Territory. In the event of an unsuccessful
Phase II or Phase III trial beyond HD, LEO shall within ************ months of the draft study report inform the Coordinating Committee of its intention to continue clinical development by presenting a development plan to the Coordinating Committee.
If LEO has not presented a development plan and provided LEO decides not to terminate the Agreement, then LEO and GTC shall agree to the annual minimum royalty obligation based on available objective financial and economic data in the manner set out
in Articles 5.2 (p) and 5.2 (q) to begin with the next calendar year following the decision by LEO not to terminate the Agreement. 
  
 5.7 Further Warranties 
  
 (a) Each of GTC and LEO represents, warrants and covenants to the others that 
  
 (i) it has the authority and right to enter into and perform this Agreement; 
  
 (ii) no authorization, consent or approval of, or any filing or registration
with, any governmental authority or regulatory body or any other Third Party (other than as contemplated by this Agreement) is required for the execution, delivery and performance of this Agreement; 
  

 17 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 (iii) the execution, delivery and performance of this Agreement will not conflict with the terms of
any other agreement to which it is or may become a party or by which it is or becomes bound and 
  
 (iv) this Agreement is a legal and valid obligation binding upon it and is enforceable against it in accordance with its terms. 
  
 (b) GTC represents and warrants that, to its knowledge as of the
Effective Date, the manufacture, use, development, sale or importation of the Product in the Territory will not infringe the intellectual property rights of any Third Parties. 
  
 (c) GTC represents and warrants that neither GTC nor any of its Affiliates is or has been a party to any agreement
with the U.S. federal government, any foreign government or an agency thereof pursuant to which the U.S. federal government, any foreign government or such agency provided funding for the development of the Product that would give the U.S. federal
government, any foreign government or any agency thereof any rights therein. 
  
 (d) GTC represents and warrants that it has made available to LEO the true and correct copies of all of the following information in its possession or control to the extent related to the development,
manufacture and commercialization of the Product as conducted to date: 
  
 (i) Adverse Event reports; 
  
 (ii) clinical study reports and material study data; and 
  
 (iii) inspection reports, notices of adverse findings, warning letters, regulatory approval filings. 
  
 (e) GTC represents and warrants that all of the studies, tests and pre-clinical and clinical trials of the Product conducted prior to, or being
conducted as of, the Effective Date have been and are being conducted in accordance with all applicable laws and regulations in all material respects. 
  
 5.8 Pharmacovigilance. Each Party shall have the reporting responsibility in its own territory and for exchange of drug related information arising
out of its own territory with the other Party. No later than ************ months after the Effective Date, the Parties shall enter into a Pharmacovigilance Agreement substantially in the form of Schedule D to govern collection, investigation and
reporting to the regulatory authorities and each other of Product-related adverse drug experience reports, quality reports and complaint reports such that each of the Parties can comply with its legal obligations worldwide. The standard operating
procedure will be promptly amended as changes in legal obligations require. 
  

 18 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 5.9 Rights for LEO to negotiate to take over certain parts of the Manufacturing During the
term of this Agreement LEO may, upon written notice to GTC, initiate good faith negotiations for the semi-exclusive right to test, purify, fill and finish (to naked vials) the Product in the Territory. Under such terms LEO shall have the right to
appoint subcontractors to perform these duties on behalf of LEO. 
  
 5.10 Not later than ************ months following the Effective Date GTC shall undertake to demonstrate to LEO that detailed back-up plans for securing adequate supplies of raw materials to meet the reasonable requirements of LEO at
all times for the Product have been fully prepared and implemented by GTC. 
  
 6. SUPPORT FOR NEW INDICATIONS 
  
 For the
purposes of this Agreement, Clinical Trials for indications other than HD shall be divided into two major types. 
  
 Clinical Studies can be categorized as: 
  
 6.1 For “Registration Studies” the paying Party can have the data filed in its Territory, i.e., if both Parties pay, the data can be
filed in both Parties’ territories. If only one Party pays, then that Party owns the data and only that Party can have the data filed in its Territory, except with respect to a ************ , which shall be paid for by LEO. 
  
 (a) LEO will fund and use its Best Efforts to progress the Program for
new indications in the Territory, with GTC having the option, but not the obligation to participate in such funding. Should LEO provide the funding for such clinical trials in the Territory, and GTC subsequently wishes to utilize the data from such
clinical trials to support approvals in jurisdictions outside the Territory, it shall compensate LEO for such use. The amount and form of such compensation and a premium, shall be negotiated by the Parties in good faith prior to the commencement of
any clinical trial, but shall be based upon the scope and costs of the clinical trials to be conducted, as well as the jurisdictions and the patient population in those jurisdictions. A similar approach shall be used if GTC pays for any clinical
trials outside the Territory and LEO wishes to use such data in support of regulatory submissions within the Territory. 
  
 LEO shall conduct a Phase II Registration Study of the Product in the ************ Indication. The design and scope of this Registration Study is to be
discussed in the Coordinating Committee. This Phase II Registration Study shall be conducted as per the scientific advice of EMEA and in the Territory. This Registration Study will be at LEO cost and all data will be shared freely between the
Parties. 
  
 As regards Phase III Registration Study for the
************ Indication, the Parties agree to the following principle in costing the Registration Study: LEO will only pay for clinical development conducted within the Territory. If a jointly funded Registration Study is performed, (i.e. including
centers both within and outside the Territory), GTC shall pay the incremental increase in cost per patient outside the Territory (US centers) over that cost per patient within the Territory and the remaining costs are to be shared ************
between the Parties. The following formula shall serve as a guide for determining the cost to be shared and the cost paid for by GTC in these types of Registration Studies: 
  
 To be shared: 
  
 ************ 
  
 To be paid by GTC: 
  
 ************ 
  

 19 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 (b) For non-clinical studies LEO will pay for requirements specifically made by EMEA for
registration of the ************ indication in the Territory subject to the prior approval by LEO of the budget for such cost. For indications beyond ************ the Parties will split the cost on a ************ basis for such non-clinical studies
in a similar manner as described above in the first paragraph of Article 6.1 (a). 
  
 6.2 For “Other Studies” the Parties can freely use the data regardless of which Party conducted and paid for the study. 
  
 7. REGULATORY REQUIREMENTS 
  
 7.1 Regulatory and Reimbursement Approvals. GTC shall obtain Approval of the MAA submitted prior to the signing of this Agreement from the European
Commission for the Product in the European Union, and promptly hereafter cause Genzyme Corporation to transfer the marketing authorization in European Union to LEO. Until the transfer of the MAA has been effected GTC shall cause Genzyme Corporation
to adhere to all reasonable instructions given by LEO from time to time in respect of engaging with the EMEA. Upon completion of the transfer LEO will act as marketing authorization holder. LEO, as Marketing Authorization holder, shall apply for
Regulatory Approvals (other than the MAA for the Product for the HD Indication in the EU) and, if applicable, Reimbursement Approvals in its own name or in the name of one of its Affiliates, distributors or agents subject to the following
conditions: 
  
 (i) that the corresponding initial application,
any material amendment to such application (including any variation in the Specifications and any content on any Product label or package insert), and any answers to questions pertaining to that part of the manufacturing process under the control of
GTC, for a country in the Territory shall be submitted to the Regulatory Authorities only after approval by the Coordinating Committee of such initial application, amendment, or answers, which approvals shall not be unreasonably withheld or delayed;

  
 (ii) that the contents of the applications shall at all times
be kept strictly confidential by LEO and GTC; and 
  
 7.2
Suspension of Distribution. Each Party shall notify the other promptly if it becomes aware of a problem with the quality or safety of the Product distributed in the Territory, or a directive from the FDA, the EMEA, or any other applicable
Regulatory Authority related to Product distributed in the Territory. Upon receipt of any such notice from GTC, LEO, in consultation with GTC, shall determine whether to immediately suspend Sales and distribution of the Product in the Territory.
After any such suspension, LEO shall in its reasonable discretion determine whether and when to resume Sales and distribution of the Product; provided, however, that no such suspension shall be deemed to be a default by LEO hereunder except to the
extent 

  

 20 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 
that LEO does not resume Sales and distribution of the Product within ************ days after the Parties agree that such quality problem has been resolved.
Should LEO resume Sales contrary to GTC’s advice substantiated in writing to LEO, LEO shall be responsible for any liability towards third parties as a result of continued Sales of such Product in the Territory. 
  
 7.3 Product Recall. Each Party shall promptly notify the other Party
of any recalls required by the FDA, the EMEA, or other applicable Regulatory Authority or Reimbursement Authority with respect to the Product. Upon such a recall, LEO and GTC shall determine if such recall is applicable to any Product lot in
distribution in the Territory and immediately notify its affected customers in the Territory using a letter containing appropriate instructions as to whether the customer should return or dispose of the affected Product. GTC shall be responsible for
any expenses incurred by LEO associated with the mailing, shipping and reasonable administrative expenses in connection with such a recall as well as the cost of replacement Product for LEO and its customers, unless the reason for the recall is
caused by the negligence of LEO, in which case LEO shall be responsible for any expenses incurred by GTC or LEO associated with the mailing, shipping and reasonable administrative expenses in connection with such a recall in the Territory as well as
the cost of replacement Product for LEO and its customers. 
  
 7.4 Records. Each Party shall maintain for two (2) years after the termination or expiration of this Agreement the systems and records specified in Article 7.3 or 7.5, as the case may be, and such other information as shall
reasonably be required to effect a recall of the Product in the Territory, and shall make such information available to the other Party, at its request, in the event of such a recall. Furthermore, each Party shall cooperate with the other Party in
investigating any Product failure which results in the need for a recall in the Territory. 
  
 7.5 Advertising and Promotional Materials. As permitted by applicable laws and regulations, all documentary information, promotional material and oral presentations (where practical) promoting the Product in
the Territory shall display (a) the trademarks, logos and trade dress of the Product in a manner that promotes the Product, and (b) the names and/or logos of each of the Parties in an appropriate manner and shall identify LEO as the
marketing authorization holder (initially GTC )as the manufacturer, and LEO as a distributor, of the Product, and ATryn® as a Trademark of GTC, unless otherwise required by applicable law, regulation or requirement of the EMEA or other Regulatory Authority. LEO shall be
responsible for reviewing and discussing all promotional material to be used in the Territory with the EMEA and other applicable Regulatory Authorities or Reimbursement Authorities in the Territory, and LEO shall file with the EMEA and any other
applicable Regulatory Authorities or Reimbursement Authorities all promotional materials in accordance with applicable regulatory requirements. 
  
 8. CONSIDERATION 
  
 Immediately upon execution of this Agreement, LEO will make a one time, nonrefundable payment to GTC of $2M USD. An additional $1M USD will be paid to GTC
upon GTC receiving notification of a positive opinion by the European Commission regarding GTC’s submission for the HD indication for the Product. If, in the reasonable discretion of LEO, to an Approval cannot be achieved within ************
month from receiving notification, then payment of said additional $1M USD shall be deferred to 5 bank days after Leo has been informed of the actual grant of the Approval. An additional $2M USD will be paid upon GTC receiving Approval. 

 

 21 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 LEO shall make the following additional payments to GTC. These payments shall be primarily, but not
exclusively used by GTC to pay for process scale-up for GTC’s capital requirements, and to expand production capacity with respect to the Product. GTC shall determine the timing for the initiation (and utilization of funds) for such process
scale-up. 
  
 8.2 In connection with clinical trial
activities in the Territory for ************ (or an alternative major indication mutually agreed by the Parties), LEO will make milestone payments to GTC according to the following schedule: 
  
 (a) ************ upon completion of a Phase II clinical trial the
results of which shall, in the opinion of GTC and LEO be sufficient to begin the process of enrolling patients for a Phase III clinical trial. 
  
 (b) ************ upon initiation of enrollment for a Phase III clinical trial; 
  
 (c) ************ upon completion of a Phase III clinical trial meeting the primary endpoints of the trial.

  
 (d) ************ upon submission of the MAA to EMEA;

  
 (e) ************ upon approval of the indication;

  
 (f) ************ upon first approval in Canada (for any
indication); and 
  
 (g) ************ upon first approval
in first country in the Middle East (for any indication); 
  
 (h) ************ in the first calendar year when annual Net Sales in the Territory reach ************ 
  
 (i) ************ in the first calendar year when annual Net Sales in the Territory reach ************ 
  
 If prior to Approval by the European Commission of the ************ Indication annual Net
Sales within one calendar year reach at least ************ LEO shall pay to GTC ************. If annual Net Sales within one calendar year reach at least ************ LEO shall pay to GTC an additional amount ************. In such an event
milestones (b) though (e) shall not apply. If one or more of milestones (b) through (e) have already been paid, the aforementioned amounts to be paid shall be reduced on a dollar-for-dollar basis. 
  
 For any other indications LEO wishes to pursue, LEO shall pay GTC pursuant to
mutually agreed upon milestones, but the Parties shall take into account the market for the indication and the cost of development for such indications, all within the overall economic framework of the Agreement. 
  

 22 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 8.3 Prior to Approval of the ************ Indication LEO will in addition to the royalty
mentioned in Article 8.6 pay a transfer price based on GTC’s Cost of Goods with no mark-ups until GTC’s Cost of Goods fall below an average ************ of Net Sales calculated in any given quarter for filled and unlabeled finished
Product. 
  
 Once GTC’s Cost of Goods goes below ************
of Net Sales in any given quarter or upon Approval of ************ Indication then LEO will in lieu of the above transfer price and in addition to the royalty mentioned below in Article 8.6 pay to GTC a transfer price based on the following
schedule: 
  
 ************ of Net Sales on the first ************
of annual Net Sales 
  
 ************ of Net Sales on the second
************ of annual Net Sales 
  
 ************ of Net Sales
thereafter based on annual Net Sales 
  
 8.4 In case GTC is
able to provide documentation to prove that Cost of Goods have increased due to a change in the Formulation of the Product by more than ************ over the average Cost of Goods for the previous twelve calendar months, then the Parties shall in
good faith enter into negotiations for a change in the transfer price accordingly. 
  
 8.5 After Approval of ************ Indication the minimum transfer price will be set at ************ per IU. Prior to Approval of the ************ Indication the maximum transfer price shall be set at
************ per IU. 
  
 8.6 LEO will pay to GTC a royalty
of ************ of Net Sales. 
  
 8.7 LEO shall pay GTC for
clinical or other non- commercial materials transferred to LEO on an ex-factory basis, at GTC’s Cost of Goods with no mark-up. 
  
 8.8 Royalty and Supply Price Accounting. The royalty payments and the Supply Price shall be prepared and reconciled as set forth in Schedule D.

  
 8.9 Quarterly Reports. Commencing with the first
calendar quarter after receipt of Approval for the HD Indication: 
  
 (a) the aggregate amount of the royalty payments accruing to GTC during such calendar quarter; 
  
 (b) the Units, gross Sales and the Net Sales of Product accrued during such calendar quarters on a country-by-country basis; 
  
 (c) the amount and basis for all deductions taken in the calculation
of Net Sales for such period; and 
  

 23 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 (d) each exchange rate used in converting into U.S. dollars any payments or other amounts
denominated in a currency other than U.S. dollars for quarterly Net Sales calculations the rate for quarterly Net Sales calculations the rate of exchange used for any involved currency must be as the average rate of exchange for the quarter in
question as announced by a mutually acceptable reference as agreed from time to time by the Parties. 
  
 (e) the timing of the reporting mentioned in this Article 8.9 will be agreed upon between the Parties within ************ days of the Effective
Date. 
  
 With respect to any calendar quarter for which no
payment is due, LEO shall so report. The chief financial officer of LEO shall state, on behalf of LEO, in each report delivered by LEO to GTC under this Article, that the contents of such report are true, correct and complete to the best of
knowledge and information by LEO. 
  
 8.10 Books of Account of
LEO; Audits. LEO shall keep, and shall require its Affiliates, to keep and complete accurate records and books of account containing data reasonably required for the computation and verification of payments due and payable. LEO shall open such
books and records upon reasonable notice during business hours for inspection by an independent certified accountant selected by GTC and reasonably acceptable to LEO, for the sole purpose of verifying the amount of payments due and payable to GTC.

  
 GTC shall not be entitled to conduct any such inspection more than once in
each calendar year during the term of this Agreement. GTC shall be responsible for all expenses of each such inspection; provided that if any inspection reveals an underpayment greater than ************ of the amounts due to GTC, and an independent
auditor conducted such inspection or verified the conclusions of such inspection made by GTC, then LEO shall pay all reasonable and documented expenses of such inspection, including without limitation the reasonable and documented expenses incurred
in connection with the verification by an independent auditor of the conclusions of the inspection by GTC auditors, if applicable. The amount of any such underpayment, together with the expenses of such inspection, shall be due and payable within
************ days after the receipt by LEO of the written report thereof. 
  
 8.11 Books of Account of GTC; Audits. GTC shall keep, and shall require its Affiliates, to keep and complete accurate records and books of account containing data reasonably required for the computation and
verification of its production costs for the Product. GTC shall open such books and records upon reasonable notice during business hours for inspection by an independent certified accountant selected by LEO and reasonably acceptable to GTC, for the
sole purpose of verifying the production costs for the Product. 
  
 LEO shall not
be entitled to conduct any such inspection more than once in each calendar year during the term of this Agreement. LEO shall be responsible for all expenses of each such inspection; provided that if any inspection reveals a deviation in the
production costs for the Product greater than ************ of the amounts claimed by GTC, and an independent auditor conducted such inspection or verified the conclusions of such inspection made by LEO, then GTC shall pay all reasonable and
documented expenses of such inspection, including without limitation the reasonable and documented expenses incurred in connection with the verification by an independent auditor of the conclusions of the inspection by GTC auditors, if applicable.
The amount of any such excess payment, together with the expenses of such inspection, shall be due and payable within ************ days after the receipt by GTC of the written report thereof. 
  

 24 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 8.12 Payment Terms. All payments to be made under this Agreement shall be payable in U.S.
dollars by certified or bank check or by wire transfer in immediately available funds to such account(s) as GTC may designate in writing to LEO. For the purposes of this Agreement, “U.S. dollars” shall mean United States dollars and any
successor currency thereof as the lawful currency of the United States of America. Subject to Article 13.1, LEO shall also pay Royalties to GTC after the expiration or termination of this Agreement with respect to any monies received by LEO pursuant
to revenues on Net Sales received after such expiration or termination. 
  
 8.13 Late Payments. In the event that any payment due from LEO under this Article 8 is not made within ************ days after such payment is due, interest shall accrue on such late payment from the date on which such amount became
due at a rate per annum equal to the prime rate established by Bank of America, in Boston, Massachusetts, or at a lower rate if required by applicable law, calculated on the number of days that lapse until such amount is paid in full; provided, that
if such payment has been delayed because it is related to a dispute raised by a Party in good faith that is undergoing the dispute resolution procedures set forth in Article 14.9 hereof, interest shall be calculated on the number of days payment is
delinquent starting on the day after such dispute is finally resolved. 
  
 8.14 Withholding of Taxes. Any withholding of taxes levied by tax authorities on the payments hereunder shall be deducted by LEO from the sums otherwise payable by it hereunder for payment to the proper tax authorities on behalf of
GTC and shall be borne by GTC. LEO agrees to cooperate with GTC in the event GTC claims exemption from such withholding or seeks deductions under any double taxation or other similar treaty or agreement from time to time in force, such cooperation
to consist of providing receipts of payment of such withheld tax, tax certificates, affidavits or other documents reasonably available to LEO. 
  
 8.15 If prior to expiration or termination of the Agreement LEO faces competition within the Territory from a transgenically produced generic
recombinant antithrombin product, and such product reaches a market share of ************ or more (in units) and the sales price in the market of such product is ************ or less of the price of the Product in the relevant country within the
Territory then the royalty rates applicable at that time in accordance this Agreement shall be reduced by ************ on a country-by-country basis. 
  
 9. TRADEMARKS 
  
 GTC is responsible for registration, maintenance and defense of the Trademarks of the Product in the Territory. 
  
 9.1 Registration of the Trademark. GTC is at its own expense responsible for obtaining a valid and useful (as decided by the Coordinating
Committee) registration of the Trademarks before approval of the Product in all countries of the Territory. 
  

 25 

 LEO shall use the Trademarks GTC has designated for the Product in the Territory (as set forth in Schedule B); provided,
however, that in the event that LEO and GTC determine in good faith that such Trademark for the Product is not suitable for the use in the Territory, then GTC shall designate another trademark for the Product in the Territory acceptable to LEO, such
acceptance not to be unreasonably withheld or delayed. 
  
 LEO shall not at any
time register, or cause to be registered, in its name or in the name of another, or authorize the use of, during or after the term of this Agreement, the Trademarks or any other trademark, name or design resembling or similar to the Trademarks.

  
 LEO acknowledges and agrees that the Trademarks are the sole and exclusive
property of GTC and that nothing herein shall be construed as transferring any ownership right or title of any kind or nature whatsoever thereto to LEO. LEO further agrees not to use any trademarks for the product other than the Trademarks.

  
 9.2. Maintenance of the Trademarks 
  
 GTC shall, at its own expense, seek and maintain the registration of the Trademarks in the
Territory throughout the Term of this Agreement 
  
 9.3 Defense
of the Trademarks 
  
 GTC shall, at its own expense survey and defend the
Trademarks. 
  
 LEO shall, immediately upon its knowledge hereof, be obliged to
inform GTC of any possible infringement of the Trademarks in the Territory. 
  
 9.4 Use of Trademarks. 
  
 LEO shall have
the right to use the Trademarks for the Territory; provided, however, that such use shall be limited to the Term and marketing and sale of the Product in the Territory, and subject to the following conditions: 
  
 LEO shall properly designate the Trademarks and the name of GTC in a manner
approved in advance in writing by GTC (such approval not to be unreasonably withheld or delayed) on the packaging of the final Product, to the extent required or permissible by the relevant Regulatory Approvals. 
  
 LEO may include the LEO word mark and the Assyrian Lion/LEO logo on all
packaging and promotional material. The packaging and promotional material shall adhere to the LEO product branding wherever and whenever legally possible, it being understood that LEO shall provide GTC with reasonable advance notice of any changes
to the LEO product branding. 
  
 All rights arising from the use
of the Trademarks in the Territory shall inure solely to GTC’s benefit, it being understood that nothing contained herein shall give LEO any ownership right or interest in the Trademarks. 
  
 If no objections raised by the authorities, use of the Trademarks shall
indicate that the Trademarks are owned and/or registered by GTC, e.g. by using the appropriate TM or ® symbol or by stating that the Trademarks are owned by GTC. 
  

 26 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 9.5 GTC Representations and Warranties. GTC hereby represents and warrants to LEO as of
the Effective Date that: 
  
 (a) To the Knowledge of GTC
there is no Third Party using or infringing any of the Trademarks in derogation of the rights granted to LEO in this Agreement. 
  
 (b) GTC has not received a notice of any interference action or litigation pending or any communication which expressly threatens an interference
action, or other litigation before any trademark office, court, or any other governmental entity in the Territory in regard to the Trademarks. 
  
 (c) The Trademarks listed on Schedule B are the only Trademarks owned or Controlled by GTC and its Affiliates covering the Product in the
Territory. 
  
 As used herein, “Knowledge of
GTC” means the actual knowledge, as of the Effective Date, of any senior executive of GTC with operational responsibility, and the persons who report directly to such person, for the subject matter of the applicable representation or
warranty while performing their duties and job responsibilities.  
  
 10. INTELLECTUAL PROPERTY RIGHTS 
  
 10.1
Acknowledgement. The Parties acknowledge that the ownership rights set forth herein are subject to the license grant set forth in Article 2.1 of this Agreement. 
  
 10.2 Ownership of Inventions. All right, title and interest in all GTC Inventions shall be owned by GTC. All right,
title and interest in all LEO Inventions shall be owned by LEO. All right, title and interest in all LEO/GTC Inventions shall be jointly owned by the Parties. Each of LEO and GTC shall promptly disclose to other Party the making, conception or
reduction to practice of Inventions by its employees or others acting on behalf of such Party. LEO has the right to sublicense LEO/GTC Inventions in the Territory provided GTC is given ************ days notice of such sublicense and that such
agreement is not inconsistent with the objectives of this Agreement. 
  
 10.3 Cooperation of Employees. Each Party represents and agrees that all employees or others acting on its behalf in performing its obligations under this Agreement shall be obligated under a binding written agreement to assign to
such Party, or as such Party shall direct, all Inventions made or conceived by such employee or other person. In the case of non-employees working for other companies or institutions on behalf of either Party, such Party, as applicable, shall obtain
licenses to the fullest extent available for all Inventions made by such non-employees on behalf of such Party, as applicable, in accordance with the policies of said company or institution. The Parties agree to undertake to enforce such agreements
(including, where appropriate, by legal action) considering, among other things, the commercial value of such Inventions. 
  
 10.4 Filing, Prosecution and Maintenance. If LEO requests GTC to file applications related to existing GTC Patent Rights in further countries
within the Territory compared to the countries specified at the time of signing of this Agreement in Schedule B, LEO shall pay such further costs related to filing and maintenance in such further countries. Each Party shall be 

  

 27 

 
responsible for the filing, prosecution and maintenance of all patent applications and patents which make up its Patent Rights and which relate to the
Program. Each Party agrees to file and prosecute patent applications and maintain the Patent Rights for which it is responsible and which relate to the Program in all countries in the Territory. Each Party shall consult with and keep the other fully
informed of important issues relating to the preparation and filing, prosecution and maintenance of such patent applications and patents, and shall furnish to the other Party copies of documents relevant to such preparation, filing, prosecution or
maintenance in sufficient time prior to filing such document or making any payment due there under to allow for review and comment by the other Party and, to the extent possible in the reasonable exercise of its discretion, the filing Party shall
incorporate all such comments. With respect to joint GTC/LEO Inventions, if any, the Parties shall determine, through the Coordinating Committee allocation of responsibilities regarding filing, prosecution and maintenance. The Parties will confer
and cooperate in good faith through the Coordinating Committee with respect to the prosecution and maintenance of Patent Rights that claim joint Inventions. 
  
 10.5 Cooperation. Each Party shall make available to the other Party (or to the other Party’s authorized attorneys, agents or representatives)
its employees, agents or consultants to the extent necessary or appropriate to enable the appropriate Party to file, prosecute and maintain patent applications and resulting patents with respect to Inventions owned by a Party and for reasonable
periods of time sufficient for such Party to obtain the assistance it needs from such personnel. Where appropriate, each Party shall sign or cause to have signed all documents relating to said patent applications or patents at no charge to the other
Party. 
  
 10.6 Notification. Each Party shall notify the
other Party of the issuance of each patent included within the Patent Rights for which the notifying Party or one of its Affiliates is responsible, giving the date of issue and patent number of each such patent. 
  
 10.7 No Other Technology Rights. Except as otherwise expressly
provided in this Agreement, under no circumstances shall a Party hereto, as a result of this Agreement, obtain any ownership interest in or other right to the patent rights or technology of the other Party, including items owned, controlled or
developed by the other Party, or transferred by the other Party to said Party at any time pursuant to this Agreement. It is understood and agreed that this Agreement does not grant either Party any license or other right in the rights of the other
Party for uses other than as specified in Article 2.1 hereof and this Article 10. 
  
 10.8 Enforcement of Patent Rights; Defense of Infringement Actions. Each Party shall promptly notify the other in writing of any actual or threatened Third Party infringement in the Field within or outside of
the Territory of a GTC Patent Right, LEO Patent Right or jointly owned Patent Right related to the Program, including infringement arising from the manufacture, use, or sale of a product competitive with a Product that is being developed or
commercialized by LEO (“Competitive Product Infringement”). 
  
 (a) Infringement of GTC Patent Rights and jointly owned Patent Rights. GTC will have the first right, but not the obligation, to bring, at its own expense and in its sole control, an appropriate action against a Third Party engaged
in any Competitive Product Infringement of a GTC Patent Right or jointly owned Patent Right. If GTC does not bring such action within ninety (90) days of notification thereof between the Parties pursuant to Article 10.8, LEO will have the
right, but not the obligation, to bring at the expense of LEO and in its sole control, such 

  

 28 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 
appropriate action to the extent such Competitive Product Infringement involves a jointly owned Patent Right or a GTC Patent Right to which LEO has a license
under this Agreement. GTC will have the right, but not the obligation, to bring, at its own expense and in its sole control, an appropriate action against a third party engaged in any infringement of a GTC Patent Right that is not a Competitive
Product Infringement. The Party not bringing an action under this Article 10.8 will be entitled to separate representation in such matter by counsel of its own choice and at its own expense, and will cooperate fully with the Party bringing such
action. 
  
 (b) Jointly owned Patent Right. With respect to
Third Party infringement of Joint Patents that is not a Competitive Product Infringement; the Parties will confer and take such action, and allocate expenses and recoveries, in such manner as they will agree. 
  
 (c) Infringement of LEO Patent Rights. LEO will have the first right,
but not the obligation, to bring, at its own expense and in its sole control, an appropriate action against a third party engaged in any Competitive Product Infringement of a LEO Patent Right. If LEO does not bring such action within ************
days of notification thereof between the Parties pursuant to Article 10.8, GTC will have the right, but not the obligation, to bring at GTC’s expense and in its sole control, such appropriate action. LEO will have the right, but not the
obligation, to bring, at its own expense and in its sole control, an appropriate action against a third party engaged in any infringement of a LEO Patent Right that is not a Competitive Product Infringement. The Party not bringing an action under
this Article 10.8 will be entitled to separate representation in such matter by counsel of its own choice and at its own expense, and will cooperate fully with the Party bringing such action. 
  
 (d) Settlement; Allocation of Proceeds. Neither Party will settle a
claim brought under this Article 10.8 involving a GTC Patent Right, LEO Patent Right or jointly owned Patent Right that would limit or restrict the ability of LEO to sell a Product in the Territory, without the prior written consent of LEO (which
consent will not be unreasonably withheld or delayed). LEO will not, without the prior written consent of GTC, settle any claim brought under this Article 10.8 involving GTC Patent Rights, LEO Patent Rights or jointly owned Patent Rights that would
(i) limit or restrict GTC’s ability to sell GTC’s products outside the Territory, (ii) permit a Third Party to sell GTC’s other products or products that infringe GTC Patent Rights, or (iii) result in an admission of
invalidity or unenforceability of any GTC Patent Rights. 
  
 10.9 GTC Representations and Warranties. GTC hereby represents and warrants to LEO as of the Effective Date that: 
  
 (d) To the Knowledge of GTC, neither the manufacture, use or sale of the Product or the practice of any of the inventions included in the GTC
Intellectual Property Rights nor the use of the Technical Information by LEO as contemplated by this Agreement infringes upon any Third Party’s Intellectual Property Rights or constitutes a misappropriation of a Third Party’s trade secrets
or other intellectual property rights. 
  
 (e) To the
Knowledge of GTC, there is no Third Party using or infringing any of the GTC Intellectual Property Rights or misappropriating or using Technical Information in derogation of the rights granted to LEO in this Agreement. 
  
 (f) GTC has obtained the assignment or exclusive licenses of all
interests and all rights of any and all Third Parties (including, but not limited to employees) with respect to the 

  

 29 

 
GTC Intellectual Property Rights. GTC has obtained the assignment or exclusive licenses of all interests and all rights of any and all Third Parties
(including, but not limited to employees) with respect to the Technical Information. 
  
 (g) GTC has not received a notice of any interference action or litigation pending or any communication which expressly threatens an interference action, or other litigation before any patent and trademark
office, court, or any other governmental entity in the Territory in regard to the GTC Intellectual Property Rights. 
  
 (h) The Intellectual Property Rights and patent applications listed on Schedule B, are the only Intellectual Property Rights owned or
Controlled by GTC and its Affiliates covering the Product in the Territory. 
  
 (i) As used herein, “Knowledge of GTC” means the actual knowledge, as of the Effective Date, of any senior executive of GTC with operational responsibility, and the persons who report directly to such
person, for the subject matter of the applicable representation or warranty while performing their duties and job responsibilities. 
  
 (j) GTC warrants that it has fully informed LEO of any material facts and/or information of material adverse significance regarding the Program.
GTC also warrants that that the information provided to LEO during due diligence is in all material respects true, accurate and complete and not misleading. 
  
 11. INDEMNIFICATION 
  
 11.1 Indemnification by GTC. With respect to Third Party claims, GTC shall defend, indemnify and hold LEO, its Affiliates, and their respective
directors, officers, employees and agents harmless from and against all liabilities, penalties, costs, losses, damages and expenses (including reasonable attorneys fees and expenses) (“Liabilities”) to the extent incurred and arising out
of or resulting from 
  
 (a) any misrepresentation, breach
of warranty or non-fulfillment of or failure to perform any agreement or covenant made under this Agreement by GTC and/or its Affiliates; 
  
 (b) the death of or any injury to any person or any damage to or loss of property arising out of or resulting from the quality, condition,
manufacture or use of the Product purchased by LEO from GTC, except to the extent that the event which is the proximate cause of such death, injury, damage or loss is caused by a negligent act or omission of LEO; 
  
 (c) any negligent act or omission of GTC or its Affiliates,
distributors, wholesalers, sub licensees or agents in the manufacture, storage, transportation or other of the Product or any other improper activity conducted by GTC under this Agreement which is the proximate cause of injury, death or property
damage to a Third Party; 
  
 (d) any negligent act or
omission of GTC or its Affiliates in connection with interactions and communications with governmental authorities; or 
  

 30 

 (e) the manufacture of the Product in a manner which infringes on the intellectual property rights
of a Third Party. 
  
 The provisions of this Article shall survive
the expiration or termination of this Agreement. 
  
 11.2
Indemnification by LEO. With respect to Third Party claims LEO shall defend, indemnify and hold GTC, its Affiliates, and their respective directors, officers, employees and agents, harmless from and against all Liabilities to the extent incurred
and arising out of or resulting from 
  
 (a)
any misrepresentation , breach of warranty or non-fulfillment of or failure to perform any agreement or covenant under this Agreement by LEO or its Affiliates; 
  
 (b) the death of or any injury to any person or any damage to or loss of property arising out of or resulting from
the marketing, distribution and sale of the Product purchased by LEO from GTC, except to the extent that the event which is the proximate cause of such death, injury, damage or loss is caused by a negligent act or omission of GTC; 
  
 (c) any negligent act or omission of LEO or its Affiliates,
distributors, wholesalers, sub licensees or agents in the promotion, marketing, distribution and sale of the Product or any other improper activity conducted by LEO under this Agreement which is the proximate cause of injury, death or property
damage to a Third Party; 
  
 (d) any negligent act or
omission of LEO or its Affiliates in connection with interactions and communications with governmental authorities; or 
  
 (e) the use or sale of the Product in the Territory, or the manufacture of the Product by LEO, in a manner which infringes on the intellectual
property rights of a Third Party; unless such event is caused by a negligent act or omission of GTC. 
  
 The provisions of this Article shall survive the expiration or termination of this Agreement. 
  
 11.3 Defense of Claim. Each Party hereto agrees to give the other
Parties 
  
 (a) prompt written notice of the institution
of any claims asserted or made, including any claims asserted or made by any governmental authority having jurisdiction, for which the other Parties might be liable under the foregoing indemnification obligations; 
  
 (b) to the extent the other Party is so obligated, but subject to
Articles 11.1 and 11.2., the opportunity to defend, negotiate and settle such claims; and 
  
 (c) reasonable assistance in the defense of such claims. 
  
 11.4 Settlements. Neither Party may settle a claim nor action covered by this Article without the prior written consent of the other Party, if such
settlement would impose any 

  

 31 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 
monetary obligation on the other Party or requires the other Party to submit to an injunction. Any payment made by a Party to settle any such claim or action
shall be at its own cost and expense. 
  
 11.5 Insurance.
Each Party shall, during the term of this Agreement, maintain commercially reasonable amounts of insurance or self-insurance given the size, nature and scope of its business from a reputable insurance carrier to cover against liability risks,
including Product liability insurance for the benefit of the other Party. Each Party shall provide the other Party with evidence of such insurance or self-insurance upon request. 
  
 12. CONFIDENTIALITY 
  
 12.1 Confidentiality. During the term of this Agreement and for a period of ************ years thereafter, each Party agrees and shall undertake to
keep the terms and conditions of this Agreement as well as any information regarding the Product, including all Technical Information, or otherwise received under this Agreement confidential and shall refrain from disclosing it to any Third Party,
unless (and to the extent) compelled to disclose by judicial or administrative process or, in the opinion of such Party’s counsel, by the requirements of applicable law or regulations (including Securities and Exchange Commission rules and
regulations), in which case the Party seeking to disclose such information shall give the other Party reasonable advance notice of such disclosure in order to permit the other Party to seek an appropriate protective order or to attempt to reach
mutual agreement regarding the portions of such information that should be subject to a request for confidential treatment, and except to the extent that such information 
  
 (i) is required to be disclosed by either Party in order to carry out its rights or obligations hereunder; 
  
 (ii) is in the public domain through no fault of the Party to which it is
furnished, including through prior public disclosure made in accordance with this Article 12; 
  
 (iii) is independently developed by the Party to which it is furnished without use of, reference to, or reliance upon, the furnishing Party’s information, as evidenced by written documentation; or 
  
 (iv) is later lawfully acquired from other sources (without obligations of
confidentiality) by the Party hereto to which it is furnished. 
  
 Notwithstanding the foregoing, the Parties shall issue a joint press release disclosing the existence and principal provisions of this Agreement, the text of which first shall have been reviewed and approved by each Party (such approval not
to be unreasonably withheld or delayed), provided that such press release shall not disclose any proprietary information of the either Party. The provisions of this Article 12 shall survive the termination or expiration of this Agreement. Each Party
also agrees not to use any confidential information of the other Party obtained by it in connection with this Agreement for any purpose other than the to fulfill its obligations hereunder. 
  

 32 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 The provisions of this Article shall survive the expiration or termination of this Agreement.

  
 13. TERM AND TERMINATION 
  
 13.1 Term. This Agreement shall become effective on the Effective
Date and, unless terminated earlier in accordance with this Article, shall continue in effect for an Initial Term expiring ************ years from the date of Approval of the Product with the European Commission for the HD Indication. 
  
 For any new indication, which the Parties may develop for the Product during
the Term the Parties shall in good faith based on the existing terms and conditions contained in this Agreement negotiate the mutual terms and conditions based on which such new indication shall be developed by the Parties. For this purpose the
Parties shall in each case negotiate and sign a written addendum to this Agreement providing for an extension of the Term and additional milestone payments, if applicable. All other terms and conditions set out in this Agreement shall remain
unchanged. 
  
 Upon expiry of the above Initial Term the Parties
shall in good faith negotiate and upon commercially reasonable terms and conditions an extension of the term before GTC shall be entitled to offer the rights to Product within the Territory to any third party. 
  
 13.2 Termination by GTC for Cause. GTC may terminate this Agreement,
either in its entirety or on a country by country basis, by giving written notice to LEO after the occurrence of either of the following events, such termination to be effective upon receipt of such notice by LEO: 
  

	 	(a)	the occurrence of an Event of Default with respect to LEO; or 

  

	 	(b)	the occurrence of any Insolvency Event involving LEO. 

  
 13.3 Termination by LEO for Cause. LEO may terminate this Agreement by giving written notice to GTC after the occurrence of any of the following
events, such termination to be effective upon receipt of such notice by GTC: 
  

	 	(a)	the occurrence an Event of Default with respect to GTC; 

  

	 	(b)	the occurrence of any Insolvency Event involving GTC; or 

  

	 	(c)	failure of the Product to receive Approval for the HD Indication by ************; or 

  

	 	(d)	if based on clinical phase II and/or phase III trials LEO does not find that there exists a clinical and/or commercial rationale for developing the Product in ************;
or 

  

	 	(e)	 a material, adverse change in the frequency or severity of Adverse Events (other than as a result of the activities which are the responsibilities of LEO
hereunder) which experiences require 

  

 33 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

	 	 
material additional or materially modified warnings in Product labeling, and as a result the distribution of the Product is significantly and adversely
affected during each of ************ consecutive months, or a recall of the Product approved by GTC (such approval not to be unreasonably withheld or delayed) or mandated by any Regulatory Authority (either within or outside the Territory) for any
reason related to safety; or 

  

	 	(f)	if at any time after Approval of the Product with the European Commission for the ************ Indication LEO informs GTC that the ongoing sale and distribution of the
Products within the Territory by LEO under this Agreement is not commercially feasible based on the minimum purchase price set out in Article 8.5 above, provided the Parties have not been able to reach a solution after consultations between the
respective CEOs of the Parties as provided for in Article 3. 

  

	 	(g)	if ATIII LLC without GTC having obtained the prior written consent of LEO as provided for above in Article 1 ceases to be an Affiliate of GTC. Notwithstanding the
aforementioned this provision shall not prevent GTC from carrying through a liquidation of ATIII LLC if so decided by GTC provided however that all rights and obligations relevant to this Agreement undertaken by ATIII LLC, including any intellectual
property right held by ATIII LLC, are maintained by GTC and not transferred to a third party. 

  
 13.4 Termination by LEO for Reasons Other than Cause. LEO may terminate this Agreement by giving written notice to GTC of the existence of an
injunction affecting the ability of LEO to sell the Product in the Territory as a result of a court decision that the Product infringes a Third Party’s patent, trademark or other intellectual property rights or if in the reasonable business
judgment of LEO the Product is likely to become the subject of infringement of a patent, trademark or other intellectual property right such termination to be effective upon receipt of such notice by GTC. 
  
 13.5 Rights and Obligations Upon Termination 
  
 (a) The Parties shall have the following rights and duties upon
termination of this Agreement or upon termination of the rights of LEO in any country in the Territory, with respect to such country: 
  
 (i) At the option of GTC and upon receipt of GTC’s written instructions, LEO shall(A) at GTC’s expense deliver to GTC, or to such other persons
as may be specified by GTC, in accordance with GTC’s written instructions, such Product in the possession of LEO as GTC may instruct, and (B) destroy all Product in the possession of LEO (any such destruction to be accomplished in
conformity with all applicable laws and regulations) other than the Product described in clause (A), in each case other than amounts of Product reasonably necessary to satisfy the obligations of LEO to Third Parties existing at the time of
termination, which amounts LEO shall be entitled to retain and use and shall pay for in accordance with the terms of this Agreement; provided, however, that such costs shall not be paid or reimbursed by GTC in the 

  

 34 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 
event that this Agreement is terminated pursuant to Article 13.2. In the event that this Agreement is terminated pursuant to Article 13.3, in cases where
Product is returned or destroyed in accordance with GTC’s instructions, GTC shall pay to LEO the following sum of monies within ************ days following receipt by GTC of the Product or notice of their destruction: (v) the amount paid
by LEO for such Product, plus (X) any non refundable taxes and duties actually paid by LEO in respect of the returned or destroyed such Product plus (Y) the reasonable, documented expenses actually incurred by LEO to return or destroy such
Product minus (Z) any amount owed to GTC by LEO pursuant to this Agreement. 
  
 (ii) Upon the termination of this Agreement for any reason, LEO shall (A) cease selling and distributing the Product, except to the extent necessary to satisfy the obligations of LEO to Third Parties existing at
the time of termination, and (B) thereafter, in accordance with GTC’s written instructions, either deliver to GTC or GTC’s designee at GTC’s Warehouse or destroy all display, point of sale, advertising and promotional materials
and any other item then in the possession of LEO bearing the Trademarks or other indicia of origin or quality, pertaining to the Product. To the extent LEO has purchased said materials from GTC, within ************ days after receipt of said
materials, GTC shall refund to LEO the amount paid to GTC by LEO for such materials, less wear and tear to such materials as received by GTC. LEO shall also promptly remove all signs, advertising, and similar materials bearing the Trademarks and
other indicia of origin or quality of the Product from the buildings of LEO, stationery and other property and advertising; provided, however, that such costs shall not be paid or reimbursed by GTC in the event that this Agreement is terminated
pursuant to Article 13.2. 
  
 (iii) Upon the expiration or
termination of this Agreement for any reason and to the extent legally permissible, LEO shall, at the expense of LEO, except in the case where the GTC breaches the Agreement, in which case GTC shall bear the cost, and without delay and without
taking recourse to legal action to prevent such transfer or assignment, transfer and assign to GTC or its designee any and all licenses, approvals and permits in the name of LEO or its Affiliates (and all documentation necessary or relating thereto)
relating to the marketing, sale, use, handling and distribution of the Product in the Territory, including without limitation Regulatory Approvals, Reimbursement Approvals and Orphan Drug designations and approvals. In the event that LEO is unable
to so transfer any Regulatory Approvals, Reimbursement Approvals or Orphan Drug designations, LEO shall, at the cost of LEO, except in the case where it has been determined by an arbitrator that GTC has breached the Agreement, in which case GTC
shall bear the cost, maintain such Regulatory Approvals, Reimbursement Approvals or Orphan Drug designations in accordance with GTC’s reasonable instructions for GTC’s exclusive benefit. 
  
 (iv) Upon termination for any reason whatsoever, GTC shall be obligated to
(and shall cause its Affiliates or any new distributor of the Product in the Territory to) (A) fulfill all post-marketing commitments of LEO or its Affiliates for the Product in the Territory (to the extent that GTC agreed in advance to the
scope of such commitments) and (B) continue to supply the Product to patients in the Territory who are receiving treatment at the time of termination. The continued supply of Product pursuant to this Article shall be on terms substantially
similar to the terms on which such Product was supplied to LEO prior to termination. 
  
 (b) The termination for any reason whatsoever of this Agreement shall not release either Party from the obligation to pay any sums then owing to the other Party or 

  

 35 

 
from the obligation to perform any other duty or to discharge any other liability that such Party has incurred prior thereto. Notwithstanding the
aforementioned in case the Agreement is terminated for other reasons than the occurrence of an Event of Default with respect to LEO, LEO shall be released from its payment obligation with respect to any milestone payments as set out in Article 8.2
to the extent such milestone payments have not fallen due when the termination becomes effective. 
  
 (c) The following provisions of this Agreement shall survive any termination of this Agreement: Articles 11, 12, 14.4, 14.7, 14.8, 14.10, 14.12,
14.15 and 14.17. 
  
 14. MISCELLANEOUS 
  
 14.1 Entire Agreement. This Agreement, together with the Schedules
hereto, sets forth the entire agreement and understanding between the Parties as to the subject matter hereof. Except as otherwise provided expressly herein, no modification, amendment or supplement to this Agreement or to such Schedules shall be
effective for any purpose unless in writing and signed by the Parties hereto. 
  
 14.2 Binding Effect; Assignment. This Agreement shall inure to the benefit of and be binding upon the Parties hereto and their respective successors and permitted assigns. Neither this Agreement nor the rights
granted or obligations assumed hereunder shall be assigned or otherwise transferred by either Party without the prior written consent of the other Party; provided, however, that either Party may assign this Agreement without the consent of the other
Party 
  
 (a) to any of its Affiliates; and 
  
 (b) to a Third Party in connection with a merger, consolidation or
sale of substantially all of such Party’s assets, provided that the assigning Party’s rights and obligations under this Agreement shall be assumed by its successor in interest in any such transaction and shall not be transferred separate
from all or substantially all of its other business assets. 
  
 An
assignment by a Party to any of its Affiliates shall, in no event, release such Party of any of its obligations hereunder. 
  
 14.3 Change of Ownership. GTC shall, in any agreement of divestiture, sale of all or substantially all of its assets or stock, or any other act which results in a
change in control of GTC, include in such agreement language which requires the acquiring party to comply with the terms and conditions of this License and Supply Agreement. 
  
 For the avoidance of doubt, in the above circumstances, LEO shall continue to have the license, trademark and trade secret rights, as are
set forth in the Agreement for the Term of the Agreement. GTC’s successor shall be obligated to (i) provide LEO the know-how, technical and regulatory support, and product supply necessary to perform its obligations under the Agreement.

  

 36 

 14.4 Governing Law. This Agreement shall be governed by, and construed in accordance with, the
laws of Switzerland, without regard to the conflicts of laws provisions thereof. 
  
 14.5 No Waiver; Remedies. Except as expressly provided herein, the waiver by any Party hereto of any right hereunder or of any failure to perform or any breach by any other Party shall not be deemed a waiver of
any other right hereunder or of any other failure to perform or breach by such other Party, whether of a similar nature or otherwise, nor shall any singular or partial exercise of such right preclude any further exercise thereof or the exercise of
any other such right. The remedies herein are cumulative and not exclusive of any remedies provided by law. 
  
 14.6 Force Majeure. No Party shall be held liable or responsible to any other Party, nor be deemed to have defaulted under or breached this
Agreement, for failure or delay in fulfilling or performing any term of this Agreement when such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, including without limitation contamination or
diseases affecting the herd of Transgenic Animals from which Product is produced, provided such event is not due to the negligence of GTC, fires, flood, earthquakes, accidents, explosions, sabotage, strikes, or other labor disturbances (regardless
of the reasonableness of the demands of labor), civil commotions, riots, invasions, acts of terrorism, wars (whether declared or not), acts, restraints, requisitions, regulations, or directions of governmental authorities, shortages of labor, fuel,
power, or raw material, inability to obtain equipment or supplies, inability to obtain or delays in transportation, acts of God, peril of the sea; provided, however, that the Party so affected shall use commercially reasonable and diligent efforts
to avoid or remove such causes of non-performance, and shall continue performance hereunder with reasonable dispatch wherever such causes are removed. Each Party shall provide the other Party with prompt written notice of any delay or failure to
perform that occurs by reason of force majeure. The Parties shall seek mutually and in good faith a resolution of the delay or the failure to perform. 
  
 14.7 Notices. Any consent, notice or report required or permitted to be given or made under this Agreement by one of the Parties to any other Party
shall be in writing, delivered personally or by facsimile (and promptly confirmed by personal delivery or courier), by a next business day delivery service of a nationally recognized overnight courier service or by courier, postage prepaid (where
applicable), addressed to such other Party at its address indicated below, or to such other address as the addressee shall have last furnished in writing to the addressor in accordance with this Article and shall be effective upon receipt by the
addressee: 
  

			
	To LEO:	    	LEO Pharma A/S
	 	    	Industriparken 55
	 	    	DK-2750
	 	    	Ballerup, Denmark
	 	    	Attn: President, CEO
	 	    	Phone: +45 44 94 58 88
	 	    	Fax: +45 72 26 32 95
		
	To GTC and ATIII LLC:	    	GTC Biotherapeutics, Inc.

  

 37 

			
	 	    	 175 Crossing Boulevard, Suite 410
 Framingham,
Massachusetts 01702
 Attention: Chairman, President and Chief Executive

	Officer	    	 
		
	 	    	 With a copy to: General Counsel
 Phone:
508-620-9700
 Fax: 508-370-5304

		
	For Adverse Events:	    	 GTC Biotherapeutics, Inc.
 175 Crossing Boulevard,
Suite 410
 Framingham, Massachusetts 01702
 Attention: Vice
President Regulatory Affairs

		
	 	    	Phone: 508-620-9700
	 	    	Fax: 508-370-5304

  
 14.8
Severability. Each Party hereby agrees that it does not intend to violate any public policy, statutory or common laws, rules, regulations, treaty or decision of any government agency or executive body thereof of any country or community or
association of countries. Should one or more provisions of this Agreement be or become invalid, the Parties hereto shall substitute, by mutual consent, valid provisions for such invalid provisions which valid provisions in their economic effect are
sufficiently similar to the invalid provisions that it can be reasonably assumed that the Parties would have entered into this Agreement with such valid provisions. In case such valid provisions cannot be agreed upon, the invalidity of one or
several provisions of this Agreement shall not affect the validity of this Agreement as a whole, unless otherwise specified herein or the invalid provisions are of such essential importance to this Agreement that it is to be reasonably assumed that
the Parties would not have entered into this Agreement without the invalid provisions. 
  
 14.9 Relationship of Parties. LEO shall act as an independent contractor which purchases the Product and resells it for its own account. Nothing in this Agreement shall constitute or be deemed to constitute
either Party as the legal representative or agent of the other, nor shall either Party have the right or authority to assume, create, or incur any liability or any obligation of any kind, expressed or implied, in the name or on behalf of the other
Party. The Parties do not intend, by entering into this Agreement, to enter into a partnership arrangement as described in the Internal Revenue Code of 1986, as amended and applicable regulations. 
  
 14.10 Dispute Resolution. All disputes arising out of or in connection
with this present Agreement shall be finally settled under the Rules of Arbitration of the International Chamber of Commerce by one or more arbitrators appointed in accordance with the said Rules. The arbitration shall be held in London, England and
shall be conducted in English. 
  
 14.11 Language. This
Agreement is executed in the English language. A translation of this Agreement may be provided for understanding; provided, however, that in the event of any discrepancy or contradiction between this original English version and any translation
hereof, this original English version shall prevail. 
  

 38 

 14.12 Performance by Affiliates. To the extent that this Agreement imposes obligations on
Affiliates of a Party, such Party agrees to cause its Affiliates to perform such obligations. Either Party may use one or more of its Affiliates to perform its obligations and duties hereunder, provided that LEO and GTC shall remain liable hereunder
for the prompt payment and performance of all their respective obligations hereunder. 
  
 14.13 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original and all of which, when taken together, shall constitute one and the same agreement. One
or more counterparts of this Agreement may be delivered via telecopier, and shall have and be deemed to have the same force and effect as an original counterpart hereof. 
  
 14.14 Interpretation. By executing this Agreement both Parties acknowledge and accept that the final draft of this
Agreement was reached by negotiation and mutual consent and the Agreement shall be deemed drafted by both Parties and shall not be interpreted against any one Party. The Parties agree that references to approvals not being unreasonably withheld
includes consideration of a number of factors, including without limitation material increases in costs, material changes in supply obligations of GTC and medical and regulatory considerations. 
  
 14.15 Limitation of Liability. WITH RESPECT TO ANY CLAIM BY ONE PARTY
AGAINST THE OTHER ARISING OUT OF THE PERFORMANCE OR FAILURE OF PERFORMANCE OF THE OTHER PARTY UNDER THIS AGREEMENT, THE PARTIES EXPRESSLY AGREE THAT THE LIABILITY OF SUCH PARTY TO THE OTHER PARTY FOR SUCH BREACH SHALL BE LIMITED UNDER THIS AGREEMENT
OR OTHERWISE AT LAW OR EQUITY TO DIRECT DAMAGES, ATTORNEYS’ FEES AND THE LIKE, AND IN NO EVENT SHALL A PARTY BE LIABLE TO THE OTHER PARTY FOR INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES, INCLUDING WITHOUT LIMITATION, LOST PROFITS.

  
 14.16 Expenses. Each Party shall pay its own expenses
except as specifically provided herein. 
  
 14.17 Use of
Names. Neither Party shall use the name of the other Party in any advertising or other form of publicity including press releases, without the prior written permission of the other Party, such permission not to be unreasonably withheld or
delayed. 
  
 [REMAINDER OF PAGE INTENTIONALLY BLANK]

  

 39 

 IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed
by their respective duly authorized officers as of the date first above written. 
  

							
	GTC BIOTHERAPEUTICS, INC.	 	LEO PHARMA A/S
				
	By:	 	 /s/ Geoffrey F. Cox

	 	By:	 	 /s/ Ernst Lunding

	Name:	 	Geoffrey F. Cox	 	Name:	 	Ernst Lunding
	Title:	 	Chairman, President and CEO	 	Title:	 	President, CEO
			
	 ATIII LLC
	 	 	 	 
				
	By:	 	 /s/ Geoffrey F. Cox

	 	 	 	 
	Name:	 	Geoffrey F. Cox	 	 	 	 
	Title:	 	President	 	 	 	 

  

 40 

 Schedule A 
  
 Territory 
  
 Europe 
  
 Albania 
 Andorra 
 Armenia 
 Austria 
 Azerbaijan 
 Belarus 
 Belgium 
 Bulgaria 
 Bosnia-Herzegovina 
 Croatia 
 Cyprus 
 Czech Republic 
 Denmark 
 Estonia 
 Finland 
 France 
 Fyrom (Former Yugoslav Republic of Macedonia) 
 Germany 
 Greece 
 Hungary 
 Iceland 
 Ireland 
 Italy 
 Kazakstan 
 Kyrgyzstan 
 Latvia 
 Liechtenstein 
 Lithuania 
 Luxembourg 
 Malta 
 Moldova 
 Monaco 
 Netherlands 
 Norway 
 Poland 
 Portugal 
 Romania 
 San Marino 
 Serbia 
 Slovakia 
 Slovenia 
 Spain 
  

 41 

 Sweden 
 Switzerland 
 Tajikistan 
 The Russian Federation 
 Turkmenistan 
 United Kingdom 
 Ukraine 
 Uzbekistan 
 Vatican State 
  
 North America 
  
 Canada 
  
 Middle East 
  
 Algeria 
 Bahrein 
 Egypt 
 Iran 
 Iraq 
 Israel 
 Jordan 
 Kuwait 
 Lebanon 
 Libya 
 Morocco 
 Oman 
 Qatar 
 Saudi Arabia 
 Sudan 
 Syria 
 Tunisia 
 Turkey 
 United Arab Emirates 
 West Bank and Gaza
Strip a.k.a. Palestine 
 Yemen 
  

 42 

 Schedule B 
  
 Intellectual Property Rights and Trademarks 
  

 43 

 Antithrombin Related Patent Rights 
  

					
	 Case Number:
	  	GTC-2	  	 
	 	  	 Title:
	  	 Isolation of Components of Interest from Milk

	 	  	 Owner:
	  	 Genzyme Corporation

	 	  	 Disclosure Status:
	  	 Filed

	 	  	 Disclosure Date:
	  	 
	 	  	 Attorney(s):
	  	 BO

  

																	
	 Country

	  	Sub Case

	  	Case Type

	  	Status

	  	 Application
 Number

	  	Filing Date

	  	 Patent
 Number

	  	Issue Date

	  	 Expiration
 Date

	 Australia
	  	 	  	ORD	  	Granted	  	62583194	  	17-Feb-1994	  	693430	  	05-Nov-1998	  	17-Feb-2014
									
	 Austria
	  	 	  	EPC	  	Granted	  	94910120.8	  	17-Feb-1994	  	804070	  	24-May-2000	  	17-Feb-2014
									
	 Belgium
	  	 	  	EPC	  	Granted	  	94910120.8	  	17-Feb-1994	  	804070	  	24-May-2000	  	17-Feb-2014
									
	 Canada
	  	 	  	ORD	  	Pending	  	2158118	  	17-Feb-1994	  	 	  	 	  	 
									
	 Denmark
	  	 	  	EPC	  	Granted	  	94910120.8	  	17-Feb-1994	  	804070	  	24-May-2000	  	17-Feb-2014
									
	 European Patent Convention
	  	 	  	ORD	  	Granted	  	94910120.8	  	17-Feb-1994	  	804070	  	24-May-2000	  	17-Feb-2014
									
	 France
	  	 	  	EPC	  	Granted	  	94910120.8	  	17-Feb-1994	  	804070	  	24-May-2000	  	17-Feb-2014
									
	 Germany
	  	 	  	EPC	  	Granted	  	94910120.8	  	17-Feb-1994	  	804070	  	24-May-2000	  	17-Feb-2014
									
	 Greece
	  	 	  	EPC	  	Granted	  	94910120.8	  	17-Feb-1994	  	804070	  	24-May-2000	  	17-Feb-2014
									
	 Ireland
	  	 	  	EPC	  	Granted	  	94910120.8	  	17-Feb-1994	  	804070	  	24-May-2000	  	17-Feb-2014
									
	 Italy
	  	 	  	EPC	  	Granted	  	94910120.8	  	17-Feb-1994	  	804070	  	24-May-2000	  	17-Feb-2014
									
	 Japan
	  	 	  	ORD	  	Pending	  	519999/94	  	17-Feb-1994	  	 	  	 	  	 
									
	 Luxembourg
	  	 	  	EPC	  	Granted	  	94910120.8	  	17-Feb-1994	  	804070	  	24-May-2000	  	17-Feb-2014
									
	 Monaco
	  	 	  	EPC	  	Granted	  	94910120.8	  	17-Feb-1994	  	804070	  	24-May-2000	  	17-Feb-2014
									
	 Netherlands
	  	 	  	EPC	  	Granted	  	94910120.8	  	17-Feb-1994	  	804070	  	24-May-2000	  	17-Feb-2014
									
	 Portugal
	  	 	  	EPC	  	Granted	  	94910120.8	  	17-Feb-1994	  	804070	  	24-May-2000	  	17-Feb-2014
									
	 Spain
	  	 	  	EPC	  	Granted	  	94910120.8	  	17-Feb-1994	  	804070	  	24-May-2000	  	17-Feb-2014
									
	 Sweden
	  	 	  	EPC	  	Granted	  	94910120.8	  	17-Feb-1994	  	804070	  	24-May-2000	  	17-Feb-2014
									
	 Switzerland
	  	 	  	EPC	  	Granted	  	94910120.8	  	17-Feb-1994	  	804070	  	24-May-2000	  	17-Feb-2014
									
	 United Kingdom
	  	 	  	EPC	  	Granted	  	94910120.8	  	17-Feb-1994	  	804070	  	24-May-2000	  	17-Feb-2014

  

 44 

					
	 Case Number:
	  	GTC-3	  	 
	 	  	 Title:
	  	 Transgenic Animals Secreting Desired Proteins into Milk

	 	  	 Owner:
	  	 Genzyme Corporation

	 	  	 Disclosure Status:
	  	 Filed

	 	  	 Disclosure Date:
	  	 
	 	  	 Attorney(s):
	  	 BO                    
PC

  

																	
	 Country

	  	Sub Case

	  	Case Type

	  	Status

	  	 Application
 Number

	  	Filing Date

	  	 Patent
 Number

	  	Issue Date

	  	 Expiration
 Date

	 Austria
	  	 	  	EPC	  	Granted	  	87303112.4	  	09-Apr-1987	  	264166	  	21-Aug-1996	  	09-Apr-2007
									
	 Belgium
	  	 	  	EPC	  	Granted	  	87303112.4	  	09-Apr-1987	  	264166	  	21-Aug-1996	  	09-Apr-2007
									
	 European Patent Convention
	  	 	  	ORD	  	Granted	  	87303112.4	  	09-Apr-1987	  	264166	  	21-Aug-1996	  	09-Apr-2007
									
	 France
	  	 	  	EPC	  	Granted	  	87303112.4	  	09-Apr-1987	  	264166	  	21-Aug-1996	  	09-Apr-2007
									
	 Germany
	  	 	  	EPC	  	Granted	  	87303112.4	  	09-Apr-1987	  	264166	  	21-Aug-1996	  	09-Apr-2007
									
	 Italy
	  	 	  	EPC	  	Granted	  	87303112.4	  	09-Apr-1987	  	264166	  	21-Aug-1996	  	09-Apr-2007
									
	 Japan
	  	 	  	ORD	  	Granted	  	87872187	  	09-Apr-1987	  	2874751	  	14-Jun-1999	  	09-Apr-2007
									
	 Japan
	  	D	  	DIV	  	Pending	  	341067/96	  	20-Dec-1996	  	 	  	 	  	 
									
	 Luxembourg
	  	 	  	EPC	  	Granted	  	87303112.4	  	09-Apr-1987	  	264166	  	21-Aug-1996	  	09-Apr-2007
									
	 Netherlands
	  	 	  	EPC	  	Granted	  	87303112.4	  	09-Apr-1987	  	264166	  	21-Aug-1996	  	09-Apr-2007
									
	 Sweden
	  	 	  	EPC	  	Granted	  	87303112.4	  	09-Apr-1987	  	264166	  	21-Aug-1996	  	09-Apr-2007
									
	 Switzerland
	  	 	  	EPC	  	Granted	  	87303112.4	  	09-Apr-1987	  	264166	  	21-Aug-1996	  	09-Apr-2007
									
	 United Kingdom
	  	 	  	EPC	  	Granted	  	87303112.4	  	09-Apr-1987	  	264166	  	21-Aug-1996	  	09-Apr-2007

  

 45 

					
	 Case Number:
	  	GTC-10	  	 
	 	  	 Title:
	  	 Transgenically Produced Antithrombin III

	 	  	 Owner:
	  	 GTC Biotherapeutics, Inc.

	 	  	 Disclosure Status:
	  	 Filed

	 	  	 Disclosure Date:
	  	 
	 	  	 Attorney(s):
	  	 BO

  

																	
	 Country

	  	Sub Case

	  	Case Type

	  	Status

	  	 Application
 Number

	  	Filing Date

	  	 Patent
 Number

	  	Issue Date

	  	 Expiration
 Date

	 Australia
	  	 	  	PCT	  	Granted	  	50262/96	  	21-Feb-1996	  	695249	  	26-Nov-1998	  	21-Feb-2016
									
	 Canada
	  	 	  	PCT	  	Pending	  	2197625	  	21-Feb-1996	  	 	  	 	  	 
									
	 European Patent Convention
	  	 	  	PCT	  	Abandoned	  	96907093.7	  	21-Feb-1996	  	 	  	 	  	 
									
	 Patent Cooperation Treaty
	  	 	  	ORD	  	Inactive	  	US96/02420	  	21-Feb-1996	  	 	  	 	  	 

  

 46 

					
	 Case Number:
	  	GTC-13	  	 
	 	  	 Title:
	  	 Purification of Biologically Active Peptides from Milk

	 	  	 Owner:
	  	 GTC Biotherapeutics, Inc.

	 	  	 Disclosure Status:
	  	 Filed

	 	  	 Disclosure Date:
	  	 
	 	  	 Attorney(s):
	  	 BO

  

																	
	 Country

	  	Sub Case

	  	Case Type

	  	Status

	  	 Application
 Number

	  	Filing Date

	  	 Patent
 Number

	  	Issue Date

	  	 Expiration
 Date

	 Australia
	  	 	  	PCT	  	Granted	  	29402/97	  	13-May-1997	  	725993	  	08-Feb-2001	  	13-May-2017
									
	 Austria
	  	 	  	EPC	  	Granted	  	97923643.7	  	13-May-1997	  	E224145	  	18-Sep-2002	  	13-May-2017
									
	 Belgium
	  	 	  	EPC	  	Granted	  	97923643.7	  	13-May-1997	  	0923308	  	18-Sep-2002	  	13-May-2017
									
	 Canada
	  	 	  	PCT	  	Pending	  	2254871	  	12-Nov-1998	  	 	  	 	  	 
									
	 Denmark
	  	 	  	EPC	  	Granted	  	97923643.7	  	13-May-1997	  	0923308	  	18-Sep-2002	  	13-May-2017
									
	 European Patent Convention
	  	 	  	PCT	  	Granted	  	97923643.7	  	13-May-1997	  	0923308	  	18-Sep-2002	  	13-May-2017
									
	 Finland
	  	 	  	EPC	  	Granted	  	97923643.7	  	13-May-1997	  	0923308	  	18-Sep-2002	  	13-May-2017
									
	 France
	  	 	  	EPC	  	Granted	  	97923643.7	  	13-May-1997	  	0923308	  	18-Sep-2002	  	13-May-2017
									
	 Germany
	  	 	  	EPC	  	Granted	  	97923643.7	  	13-May-1997	  	69715641.9	  	18-Sep-2002	  	13-May-2017
									
	 Greece
	  	 	  	EPC	  	Granted	  	3041974	  	13-May-1997	  	3041974	  	18-Sep-2002	  	13-May-2017
									
	 Ireland
	  	 	  	EPC	  	Granted	  	97923643.7	  	13-May-1997	  	0923308	  	18-Sep-2002	  	13-May-2017
									
	 Italy
	  	 	  	EPC	  	Granted	  	97923643.7	  	13-May-1997	  	33142BE/02	  	18-Sep-2002	  	13-May-2017
									
	 Japan
	  	 	  	PCT	  	Pending	  	99541036	  	13-May-1997	  	 	  	 	  	 
									
	 Luxembourg
	  	 	  	EPC	  	Granted	  	97923643.7	  	13-May-1997	  	0923308	  	18-Sep-2002	  	13-May-2017
									
	 Monaco
	  	 	  	EPC	  	Granted	  	97923643.7	  	13-May-1997	  	0923308	  	18-Sep-2002	  	13-May-2017
									
	 Netherlands
	  	 	  	EPC	  	Granted	  	97923643.7	  	13-May-1997	  	0923308	  	18-Sep-2002	  	13-May-2017
									
	 New Zealand
	  	 	  	PCT	  	Granted	  	332916	  	13-May-1997	  	332916	  	07-Sep-2000	  	13-May-2017
									
	 Patent Cooperation Treaty
	  	 	  	ORD	  	Inactive	  	US97/06644	  	13-May-1997	  	 	  	 	  	 
									
	 Portugal
	  	 	  	EPC	  	Granted	  	97923643.7	  	13-May-1997	  	0923308	  	18-Sep-2002	  	13-May-2017
									
	 Spain
	  	 	  	EPC	  	Granted	  	97923643.7	  	13-May-1997	  	0923308	  	18-Sep-2002	  	13-May-2017
									
	 Sweden
	  	 	  	EPC	  	Granted	  	97923643.7	  	13-May-1997	  	0923308	  	18-Sep-2002	  	13-May-2017
									
	 Switzerland
	  	 	  	EPC	  	Granted	  	97923643.7	  	13-May-1997	  	0923308	  	18-Sep-2002	  	13-May-2017
									
	 United Kingdom
	  	 	  	EPC	  	Granted	  	97923643.7	  	13-May-1997	  	0923308	  	18-Sep-2002	  	13-May-2017

  

 47 

					
	 Case Number:
	  	GTC-35	  	 
	 	  	 Title:
	  	 Transgenically Produced Antithrombin III and Mutants Thereof

	 	  	 Owner:
	  	 GTC Biotherapeutics, Inc.

	 	  	 Disclosure Status:
	  	 Filed

	 	  	 Disclosure Date:
	  	 
	 	  	 Attorney(s):
	  	 BO

  

																	
	 Country

	  	Sub Case

	  	Case Type

	  	Status

	  	 Application
 Number

	  	Filing Date

	  	 Patent
 Number

	  	Issue Date

	  	 Expiration
 Date

	 Australia
	  	 	  	PCT	  	Published	  	50083/00	  	12-May-2000	  	 	  	 	  	 
									
	 Canada
	  	 	  	PCT	  	Published	  	2,368,608	  	12-May-2000	  	 	  	 	  	 
									
	 European Patent Convention
	  	 	  	PCT	  	Published	  	00932348.6	  	12-May-2000	  	 	  	 	  	 
									
	 Patent Cooperation Treaty
	  	 	  	ORD	  	Inactive	  	US00/13052	  	12-May-2000	  	 	  	 	  	 

  

 48 

					
	 Case Number:
	  	GTC-43	  	 
	 	  	 Title:
	  	Methods of Producing a Target Molecule in a Transgenic Animal and Purification of the Target Molecule
	 	  	 Owner:
	  	 GTC Biotherapeutics, Inc.

	 	  	 Disclosure Status:
	  	 Filed

	 	  	 Disclosure Date:
	  	 
	 	  	 Attorney(s):
	  	 BO

  

																	
	 Country

	  	Sub Case

	  	Case Type

	  	Status

	  	 Application
 Number

	  	Filing Date

	  	 Patent
 Number

	  	Issue Date

	  	 Expiration
 Date

	 Australia
	  	 	  	PCT	  	Published	  	80254/00	  	16-Oct-2000	  	 	  	 	  	 
									
	 Brazil
	  	 	  	PCT	  	Abandoned	  	P10014860-1	  	16-Oct-2000	  	 	  	 	  	 
									
	 Canada
	  	 	  	PCT	  	Pending	  	2,382,741	  	16-Oct-2000	  	 	  	 	  	 
									
	 China (Peoples Republic)
	  	 	  	PCT	  	Published	  	00815280.2	  	16-Oct-2000	  	 	  	 	  	 
									
	 European Patent Convention
	  	 	  	PCT	  	Published	  	00970945.2	  	16-Oct-2000	  	 	  	 	  	 
									
	 Hungary
	  	 	  	PCT	  	Abandoned	  	P0203537	  	16-Oct-2000	  	 	  	 	  	 
									
	 India
	  	 	  	PCT	  	Abandoned	  	2002,00461/MUM	  	16-Oct-2000	  	 	  	 	  	 
									
	 Indonesia
	  	 	  	PCT	  	Abandoned	  	W-00200200831	  	16-Oct-2000	  	 	  	 	  	 
									
	 Israel
	  	 	  	PCT	  	Pending	  	1245003	  	16-Oct-2000	  	 	  	 	  	 
									
	 Japan
	  	 	  	PCT	  	Published	  	2001-529255	  	16-Oct-2000	  	 	  	 	  	 
									
	 Korea, Republic of
	  	 	  	PCT	  	Pending	  	10-2002-7004804	  	16-Oct-2000	  	 	  	 	  	 
									
	 Mexico
	  	 	  	PCT	  	Pending	  	PAW/2002  003702	  	16-Oct-2000	  	 	  	 	  	 
									
	 New Zealand
	  	 	  	PCT	  	Granted	  	518263	  	16-Oct-2000	  	518263	  	05-Jul-2004	  	16-Oct-2020
									
	 Norway
	  	 	  	PCT	  	Abandoned	  	2002 1086	  	16-Oct-2000	  	 	  	 	  	 
									
	 Patent Cooperation Treaty
	  	 	  	ORD	  	Inactive	  	US00/28589	  	16-Oct-2000	  	 	  	 	  	 
									
	 Russian Federation
	  	 	  	PCT	  	Abandoned	  	2002112460	  	16-Oct-2000	  	 	  	 	  	 
									
	 Singapore
	  	 	  	PCT	  	Granted	  	200201824-0	  	16-Oct-2000	  	88117	  	31-Mar-2004	  	16-Oct-2020
									
	 Ukraine
	  	 	  	PCT	  	Abandoned	  	2002053900	  	16-Oct-2000	  	 	  	 	  	 

  

 49 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

					
	 Case Number:
	  	GTC-62	  	 
	 	  	 Title:
	  	 Treatment of Lung Disorders

	 	  	 Owner:
	  	 University of Texas Medical Branch

	 	  	 Disclosure Status:
	  	 Filed

	 	  	 Disclosure Date:
	  	 
	 	  	 Attorney(s):
	  	 BO

  

																	
	 Country

	  	Sub Case

	  	Case Type

	  	Status

	  	 Application
 Number

	  	Filing Date

	  	 Patent
 Number

	  	Issue Date

	  	 Expiration
 Date

	 Australia
	  	 	  	PCT	  	Pending	  	2003233482	  	25-Mar-2003	  	 	  	 	  	 
									
	 Canada
	  	 	  	PCT	  	Pending	  	2480790	  	25-Mar-2003	  	 	  	 	  	25-Mar-2023
									
	 China (Peoples Republic)
	  	 	  	

PCT	  	Pending	  	03807463.X	  	25-Mar-2003	  	 	  	 	  	 
									
	 European Patent Convention
	  	 	  	

PCT	  	Pending	  	03728277.9	  	25-Mar-2003	  	 	  	 	  	 
									
	 Hong Kong
	  	 	  	ORD	  	Unfiled	  	 	  	 	  	 	  	 	  	 
									
	 Israel
	  	 	  	PCT	  	Pending	  	164078	  	25-Mar-2003	  	 	  	 	  	 
									
	 Japan
	  	 	  	PCT	  	Published	  	2003-581716	  	25-Mar-2003	  	 	  	 	  	 
									
	 Korea, Republic of
	  	 	  	PCT	  	Pending	  	10-2004-7015636	  	25-Mar-2003	  	 	  	 	  	 
									
	 New Zealand
	  	NP	  	PCT	  	Pending	  	535487	  	25-Mar-2003	  	 	  	 	  	 
									
	 Patent Cooperation Treaty
	  	 	  	

ORD	  	Published	  	PCT/US2003/009053	  	25-Mar-2003	  	 	  	 	  	 

  

					
	 Case Number:
	  	GTC-221	  	 
	 	  	Title:	  	************
	 	  	 Owner:
	  	 ************

	 	  	 Disclosure Status:
	  	 ************

	 	  	 Disclosure Date:
	  	 
	 	  	 Attorney(s):
	  	 ************

  

																	
	 Country

	 	Sub Case

	 	Case Type

	 	Status

	 	 Application
 Number

	 	Filing Date

	 	 Patent
 Number

	 	Issue Date

	 	 Expiration
 Date

	 ************
	 	************	 	************	 	************	 	************	 	************	 	 	 	 	 	 

  

 50 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

					
	 Case Number:
	  	GTC-224	  	 
	 	  	 Title:
	  	 ************

	 	  	 Owner:
	  	 ************

	 	  	 Disclosure Status:
	  	 ************

	 	  	 Disclosure Date:
	  	 
	 	  	 Attorney(s):
	  	 ************

  

																	
	 Country

	  	Sub Case

	 	Case Type

	 	Status

	 	 Application
 Number

	 	Filing Date

	 	 Patent
 Number

	  	Issue Date

	  	 Expiration
 Date

	 ************
	  	************	 	************	 	************	 	************	 	************	 	 	  	 	  	************

  

					
	 Case Number:
	  	GTC-226	  	 
	 	  	 Title:
	  	 ************

	 	  	 Owner:
	  	 ************

	 	  	 Disclosure Status:
	  	 ************

	 	  	 Disclosure Date:
	  	 
	 	  	 Attorney(s):
	  	 ************

  

																	
	 Country

	  	Sub Case

	  	Case Type

	 	Status

	 	 Application
 Number

	 	Filing Date

	 	 Patent
 Number

	  	Issue Date

	  	 Expiration
 Date

	 ************
	  	 	  	************	 	************	 	************	 	************	 	 	  	 	  	 

  

					
	 Case Number:
	  	GTC-228	  	 
	 	  	 Title:
	  	 ************

	 	  	 Owner:
	  	 ************

	 	  	 Disclosure Status:
	  	 ************

	 	  	 Disclosure Date:
	  	 
	 	  	 Attorney(s):
	  	 ************

  

																	
	 Country

	  	Sub Case

	 	Case Type

	 	Status

	 	 Application
 Number

	 	Filing Date

	  	 Patent
 Number

	  	Issue Date

	  	 Expiration
 Date

	 ************
	  	************	 	************	 	************	 	************	 	 	  	 	  	 	  	 

  

 51 

 TRADEMARK STATUS REPORT 
  

													
	 Mark

	  	Class(es)

	  	Filed

	  	Appln #

	  	Reg Date

	  	Reg #

	  	Status

	 ATRYN
	  	 	  	 	  	 	  	 	  	 	  	 
							
	 EUROPEAN UNION (CTM)
	  	5, 10, 42	  	06/15/01	  	2261691	  	05/28/03	  	2261691	  	REGISTERED
							
	 UNITED STATES
	  	5	  	12/20/00	  	76/184,729	  	07/29/03	  	2,743,233	  	REGISTERED
							
	 GTC BIO
	  	 	  	 	  	 	  	 	  	 	  	 
							
	 UNITED STATES
	  	1, 5, 31, 40, 42, 44	  	04/16/02	  	78/121,989	  	 	  	 	  	ALLOWED
							
	 GTC BIOLOGICS
	  	 	  	 	  	 	  	 	  	 	  	 
							
	 UNITED STATES
	  	1, 5, 31, 40, 42, 44	  	03/25/02	  	78/117,247	  	 	  	 	  	ALLOWED
							
	 GTC BIOTHERAPEUTICS
	  	 	  	 	  	 	  	 	  	 	  	 
							
	 EUROPEAN UNION (CTM)
	  	1, 5, 31, 40, 42	  	03/19/02	  	2623288	  	06/30/04	  	2623288	  	REGISTERED
							
	 UNITED STATES
	  	1, 5, 31, 40, 42, 44	  	03/25/02	  	78/117,241	  	 	  	 	  	ALLOWED
							
	 GTC PHARMACEUTICALS
	  	 	  	 	  	 	  	 	  	 	  	 
							
	 UNITED STATES
	  	1, 5, 31, 40, 42, 44	  	03/25/02	  	78/117,254	  	 	  	 	  	ALLOWED
							
	 ZYVESTA
	  	 	  	 	  	 	  	 	  	 	  	 
							
	 UNITED STATES
	  	1, 5, 31, 40, 42	  	02/05/01	  	76/205,984	  	 	  	 	  	ABANDONED

  

 52 

 Schedule C 
  
 QA/QC Agreement for Pharmaceutical Products on Contract Manufacture 
  
 (The Parties to elaborate further on LEO separately forwarded proposal for
a standard agreement) 
  

 53 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 Schedule D 
  
 Procedure for Ordering and Forecasting of Products for Clinical Trials and commercial Sale and Distribution

  

			
	 Forecast
	  	In respect of commercial supplies GTC will, within ************ working days following the end of each calendar month, receive from LEO a rolling forecast covering ************ months of
which the first ************ month must be covered by firm orders (consisting of the then current month and the following ************ months.
		
	 	  	In respect of supplies of the Product for clinical trials GTC will, within ************ working days following the end of each calendar quarter, receive from LEO firm rolling orders covering
the current month plus ************ months.
		
	 	  	Failure by GTC to supply sufficient amounts of Product based on the above forecasting shall not constitute a breach of this Agreement by GTC, provided such inability is caused by an increase
in the forecast by more than *********** percent compared to the previous forecast received from LEO.
		
	Orders	  	LEO will no later than within ************ working days following the end of each calendar month place such orders as required in order to comply with the commitments of the
forecast.
		
	 	  	GTC will deliver the ordered Products in such quantities, at such time and to such destination as specified by LEO. LEO will issue separate purchase orders for commercial and clinical
supplies. Received orders shall reference the appropriate purchase order from LEO.
		
	Purchase Price	  	The purchase price will be as per article 8 of the Licensing and Supply Agreement
	
	Invoicing and payment
		
	 	  	GTC shall issue an invoice to with each shipment of Product pursuant to the Licensing and Supply Agreement and LEO agrees to pay such invoice within ************ days from date of
invoice.
		
	 	  	The supply price of Product shall reflect the shipping terms FCA [Site of Production] (ICC Incoterms 2000)

  

 54 

			
	 	  	Invoicing and payments for Product shall be denominated in United States Dollars (USD).
	 	  	Payments shall be made to an account designated by GTC in writing.
		
	 Invoice Adjustments
	  	 
	 	  	Because the Purchase Price is based on Net Sales and will not be known precisely at the time of shipment of Product by GTC, such invoice price shall reflect an estimated Purchase Price agreed
by the parties.
		
	 	  	Estimated transfer prices shall be set quarterly in advance and shall be adjusted to actual quarterly in arrears with a final true-up at the end of the calendar year.

  

 55 

 Schedule E 
  
 Pharmacovigilance Procedures Agreement 
  
 (LEO standard agreement to be further elaborated) 
  
 PHARMACOVIGILANCE PROCEDURES AGREEMENT 
  
 (The “Agreement”) 
  
 Between 
  
 GTC Biotherapeutics, Inc. 
 175 Crossing Boulevard, Suite 410 
 Framingham, Massachusetts 01702 
 U.S.A.

  
 (Referred to as GTC) 
  
 and 
  
 LEO Pharma A/S 
 Industriparken 55 
 2750 Ballerup 
 Denmark 
  
 (Referred to as LEO) 
  

 56 

 On 31 October 2005 GTC and LEO have entered into a license and supply agreement (hereinafter referred to as the
Licensing and Supply Agreement) regarding the import, storage, distribution, use and sale of Products in the Territory. With reference to Article 5.8 of the Licensing and Supply Agreement the parties have entered into this Agreement regarding a
Clinical Studies and Post-Marketing Surveillance Operation.  
  
 § 1. This Agreement 
  
 This
Agreement concerns the ‘Product’ , and ‘Territory’ as defined in the Licensing and Supply Agreement. 
  
 § 2. Scope of the Agreement 
  
 The procedures, time frames and responsibilities which GTC and the Drug Safety Department of LEO (hereinafter referred to as LEO Drug Safety Department) will adopt to
ensure compliance with the regulatory requirements of Clinical Studies and Post-Marketing Surveillance are as described in this Agreement. 
  
 The Pharmacovigilance procedures agreed upon herein reflect ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting. However,
these guidelines shall, inter partes, apply only as a minimum, being understood that national pharmacovigilance legislation applicable in the Territory shall be abided by and prevail to the extent such national pharmacovigilance legislation is more
restrictive than stated in this Agreement. 
  
 § 3. Medical
Definitions 
  
 ‘Suspected Adverse Drug Reactions’
(‘SADR’) shall mean a response to a drug which is noxious and unintended and which occurs at doses normally used in man for prophylaxis, diagnosis, or therapy of diseases or for modification of physiological function (see ICH Topic E 2 A
Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). 
  
 ‘Serious Suspected Adverse Drug Reaction’ (‘SSADR’) shall mean any untoward medical occurrence that, at any dose: 
  

	•	 	results in death 

  

	•	 	is life-threatening 

  

	•	 	requires inpatient hospitalization or prolongation of existing hospitalization 

  

	•	 	results in persistent or significant disability/incapacity 

  

	•	 	is a congenital anomaly/birth defect 

  

	•	 	results in other medically important conditions 

  
 (See ICH Topic E 2 A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting.) 
  

 57 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 ‘Unexpected Adverse Drug Reaction’ (‘UADR’) shall mean an adverse drug reaction, the
nature or severity of which is not consistent with the applicable product information e.g., product or package insert/summary of product characteristics (SmPC) for an approved product filed with the applicable National Health Authorities.

  
 ‘Serious Unexpected Adverse Drug Reaction’
(‘SUADR’) shall mean an adverse drug reaction which is both serious and unexpected. 
  
 ‘Date of First Receipt’ (‘DFR’) shall mean the calendar date when the first person at either LEO or GTC is notified of an adverse drug reaction. 
  
 § 4. Database 
  
 LEO Drug Safety Department will be responsible for maintaining a complete safety database.

  
 § 5. SADR Data Exchange 
  
 Data exchange will be between the LEO Drug Safety Department and GTC in accordance with the
procedures set forth below. The language of all data exchange will be English. 
  
 Post marketing SADR reports 
  
 SSADRs 
  
 GTC receives Post marketing SSADR 
  

	 	•	 	For cases with fatal outcome or which are life-threatening an alert should be faxed to LEO within ************ calendar days of first receipt 

  

	 	•	 	GTC forwards by fax (+45 72263287) CIOMS report for all SSADR reports to LEO within ************ calendar days of date of first receipt 

  

	 	•	 	LEO confirms receipt of fax via fax to GTC 

  

	 	•	 	LEO databases SSADR 

  
 LEO receives Post marketing SSADR 
  

	 	•	 	LEO notifies GTC by fax (fax No.) of all SSADR reports regardless of medically validated status within ************ calendar days 

  

	 	•	 	LEO forwards CIOMS report to GTC by fax (fax No.) within ************ calendar days of date of first receipt. 

  

	 	•	 	GTC confirms receipt of fax via fax to LEO 

  
 Non-serious ADRs 
  
 GTC will by mail on a monthly basis send a line listing of all non-serious ADRs originating from outside the territory to LEO Drug Safety Department. 
  
 LEO will by mail on a monthly basis send a line listing of all non-serious ADRs originating from the territory to GTC. 
  

 58 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 Reports from Literature 
  
 LEO Drug Safety Department will have the primary responsibility for reviewing the literature. GTC will assist by notifying of case reports
from literature brought to its knowledge from outside the Territory. Reports will be exchanged as for Post Marketing SADR reports. 
  
 SSADR Reports from Clinical Trials 
  
 All SSADR Reports from Clinical Trials which are considered related to the investigational product by either the reporter or the sponsor will be exchanged with a
causality assessment. 
  
 GTC will complete causality assessment according to GTCs
procedure. 
  
 LEO will complete causality assessment according to the procedure
of LEO. 
  
 GTC receives Clinical SSADR considered related to the
investigational product 
  

	 	•	 	For cases with fatal outcome or which are life-threatening an alert should be faxed to LEO within ************ calendar days of first receipt 

  

	 	•	 	GTC forwards by fax (+45 72263287) CIOMS report for all SSADR reports to LEO within ************ calendar days of date of first receipt 

  

	 	•	 	LEO confirms receipt of fax via fax to GTC 

  

	 	•	 	LEO databases SSADR 

  
 LEO receives Clinical SSADR considered related to the investigational product 
  

	 	•	 	LEO notifies GTC by fax (fax No.) of all SSADR reports within ************ calendar days 

  

	 	•	 	LEO forwards CIOMS report to GTC by fax (fax No.) within ************ calendar days of date of first receipt. 

  

	 	•	 	GTC confirms receipt of fax via fax to LEO 

  
 LEO will inform ethic committees and investigators as required in the Territory. 
  

GTC will inform ethics committees and investigators as required outside the territory. 
  
 § 6. Pregnancy cases 
  
 Information on pregnancy cases will be exchanged between the parties as described for an SSADR above (SSADR reports from clinical trials). 
  

 59 

 § 7. Notification of Regulatory Authorities 
  
 LEO will be responsible for appropriate regulatory notifications in the Territory.

  
 GTC will be responsible for appropriate regulatory notifications outside the
Territory. 
  
 § 8. Regulatory Authority Requests for
Additional Information 
  
 Additional Information to an Individual Case
Report: 
  
 The party receiving an individual ADR report first will be
responsible for obtaining the requested information from the reporter. 
  
 Additional Safety Information of a more General Nature: 
  
 Regulatory authority requests for safety information of a more general nature in the Territory will be handled by LEO Drug Safety Department and GTC together. The response will be submitted by LEO to the authority in the Territory.

  
 § 9. Safety Reports 
  
 LEO has the responsibility for preparing PSURs, Annual Safety Reports, periodic line listings
as as requested by the authorities in the Territory. 
  
 LEO will provide GTC with
PSURs and line listings of non-medically confirmed cases on request. 
  
 § 10. Signaling 
  
 LEO Drug Safety Department will be
responsible for identifying new risks of the product and for informing GTC immediately thereof. GTC will inform LEO Drug Safety Department of any safety concerns identified by GTC. 
  
 LEO Drug Safety will ensure inclusion of new safety information in the Investigator’s Brochure and in the Company Core Safety
Information (CCSI). 
  
 § 11. Audit 
  
 GTC shall be entitled to audit LEO’s Pharmacovigilance systems at any time, upon
reasonable notice and during normal business hours, to ensure that the provisions of this Agreement are complied with by LEO. 
  

 60 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 § 12. Contact Persons 
  

			
	LEO Pharma A/S
	Alice Brinch Moerch, MD
	Medical Director, Drug Safety
	Tel:	  	+45 72262849
	Fax:	  	+45 72263287
	E-mail:	  	alice.moerch@leo-pharma.com
	 	  	drug.safety@leo-pharma.com
	
	GTC Biotherapeutics, Inc.
	Richard A. Scotland
	Vice President, Regulatory Affairs
	Tel:	  	+1 5083705164
	Fax:	  	+1 5089047597
	E-mail:	  	dick.scotland@gtc-bio.com

  
 Any changes in contact persons shall
be communicated in writing to the other party without undue delay. 
  
 § 13. Changes in Regulatory Requirements 
  
 GTC and LEO
agree to update this Agreement according to any changes made in the marketing authorization or in regulatory requirements. 
  
 § 14. Confidentiality 
  
 Information and data exchanged under this Agreement shall be considered as confidential information. Such confidentiality obligation will survive the termination of this
Agreement by a period of ************ years. 
  
 This obligation shall not apply
to: 
  

	 	•	 	Information which is required by law or regulation to be reported to the authorities, such information shall, however, only be disclosed to the relevant authorities;

  

	 	•	 	Information which, at the time of disclosure, is already in the public domain; 

  

	 	•	 	Information which, after disclosure, becomes a part of the public domain by publication through no violation of this Agreement; 

  

	 	•	 	Information which the receiving party is able to prove to have been in possession of prior to any disclosure. In this case, such party will demonstrate that it is in possession of
this information in writing within ************ days of receipt of information, or forego application of this provision; 

  

	 	•	 	Information which is hereafter lawfully disclosed by a third party to the receiving party, where third party did not acquire the information under a still effective obligation of
confidentiality to the other party. 

  

 61 

 Confidential material omitted and filed separately with the Securities and Exchange Commission. Asterisks denote
such ommissions. 
  

 § 15. Term and Termination 
  
 This Agreement will be effective from the date of the last signature of the Agreement, provided however that the Licensing and Supply
Agreement is in force at this date. If the License and Supply Agreement is not effective at the date of the last signature of this Agreement, then this Agreement will be effective at the effective date of the License and Supply Agreement.

  
 This Agreement will be automatically terminated at the date of termination or
expiration of the License and Supply Agreement. The parties agree, however, that after termination of this Agreement, the parties will collaborate on fulfilling the responsibilities of reporting to the authorities, insofar as reporting is required
by law. 
  
 Any breach of this Agreement which is not remedied within ************
days, shall also be considered a material breach of the License and Supply Agreement. 
  
 § 16. Inconsistencies 
  
 To the
extent of any conflict or inconsistency between this Agreement and the License and Supply Agreement, the terms of the License and Supply Agreement shall control, unless otherwise agreed to in writing between the parties. 
  
 § 17. Assignability 
  
 In case a party assigns, transfers or sub-contracts, in whole or in part, any of its rights
and obligations under this Agreement, the party has an obligation to inform the other party. 
  
 § 18. Force Majeure 
  
 No party
hereto shall be liable for the non-performance of its obligations set forth in this Agreement and no party shall be deemed in breach of its obligations if such non-performance is due to force majeure: 
  
 i.e. natural disaster, strikes, civil war or other circumstances beyond the reasonable
control of such party, provided such force majeure cannot be overcome by exercising due diligence and provided that the party failing to perform its obligations notifies the other party as soon as possible of the occurrence. 
  

 62 

 § 19. Controversy 
  
 In the event of any controversy or claim arising out of or relating to any provision of this Agreement or the breach or invalidity hereof,
the parties shall try to settle the problem amicably between themselves. Should they fail to agree, the matter in dispute shall be settled in accordance with the provisions on controversy of the License and Supply Agreement. 
  

			
	LEO Pharma A/S	 	GTC Biotherapeutics, Inc.
		
	Dated:	 	Dated:
		
	
	 	

	 Alice Brinch Moerch
 Medical Director, Drug
Safety
	 	 Richard A. Scotland
 Vice President, Regulatory
Affairs

  

 63

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00094-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00094-of-00352.parquet"}]]